ICG Tail Emission NIR-II Imaging: A Practical Guide for Clinical Translation in Biomedical Research

Abstract

This article provides a comprehensive analysis of Indocyanine Green (ICG) tail emission in the second near-infrared window (NIR-II, 1000-1700 nm) for clinical translation. Targeting researchers, scientists, and drug development professionals, it explores the fundamental photophysics of ICG's NIR-II fluorescence, details optimized imaging methodologies and surgical/non-surgical applications, addresses critical troubleshooting and signal optimization challenges, and validates performance through comparative studies with other agents and modalities. The synthesis offers a clear roadmap for leveraging this clinically approved dye for advanced, deep-tissue imaging in oncology, vascular surgery, and functional monitoring.

Unlocking ICG's Hidden Signal: The Science Behind NIR-II Tail Emission and Clinical Potential

Application Notes

Near-infrared window II (NIR-II, 1000-1700 nm) imaging represents a significant advancement over traditional NIR-I (700-900 nm) imaging for in vivo biomedical applications. The primary advantage lies in reduced photon scattering and minimal autofluorescence within biological tissues in the NIR-II region, leading to superior spatial resolution, increased signal-to-background ratio (SBR), and greater penetration depth. This is critically important for clinical translation, particularly when leveraging the tail emission of the FDA-approved dye Indocyanine Green (ICG) beyond 1000 nm. For researchers focused on preclinical drug development and clinical translation, NIR-II imaging facilitates more accurate visualization of deep-tissue structures, tumor margins, and real-time vascular dynamics.

Quantitative Comparison of NIR-I vs. NIR-II Windows

Table 1: Photophysical Properties and Performance Metrics of NIR-I vs. NIR-II Imaging

Parameter	NIR-I Window (700-900 nm)	NIR-II Window (1000-1700 nm)	Implication for Deep Tissue Imaging
Photon Scattering	High (∝ λ^-4)	Significantly Reduced (∝ λ^-0.5 to λ^-2)	NIR-II provides sharper images with higher resolution at depth.
Tissue Autofluorescence	High	Very Low to Negligible	NIR-II yields superior Signal-to-Background Ratio (SBR > 5-10x NIR-I).
Optical Penetration Depth	Moderate (1-3 mm)	Enhanced (3-10 mm)	Enables non-invasive visualization of deeper anatomical and pathological features.
Maximum Spatial Resolution	~20-40 μm at 1 mm depth	~10-25 μm at 2 mm depth	Finer anatomical detail can be resolved.
Optimal SBR for ICG	~2-5 (peak at ~800 nm)	~10-50 (tail emission >1000 nm)	ICG's tail emission, though weaker, provides clearer contrast in NIR-II.
Tissue Absorption	Moderate (Hb, HbO₂, H₂O)	Lower (Minimal Hb/HbO₂, rising H₂O >1400 nm)	"Biological transparency window" is wider in NIR-II, especially 1000-1350 nm.

Table 2: Performance of ICG in NIR-I vs. NIR-II Sub-Windows In Vivo

Imaging Window	Central Wavelength (nm)	ICG Emission State	Typical SBR (Vessel Imaging)	Achievable Resolution at 3 mm Depth
NIR-I	800-850	Primary Peak	3.2 ± 0.8	~150 μm
NIR-IIa	1000-1300	Tail Emission	15.3 ± 3.5	~65 μm
NIR-IIb	1300-1500	Tail Emission	8.1 ± 2.1	~80 μm

Experimental Protocols

Protocol 1: NIR-II Imaging of Vasculature Using ICG Tail Emission

Objective: To acquire high-resolution, deep-tissue images of the murine cerebral or hindlimb vasculature using the NIR-II tail emission of ICG.

Materials: See "The Scientist's Toolkit" below.

Procedure:

• Animal Preparation: Anesthetize the mouse (e.g., C57BL/6) using isoflurane (2-3% for induction, 1-2% for maintenance). Secure the mouse on a heated stage to maintain body temperature. For cranial imaging, perform a scalp incision and carefully clear the skull.
• ICG Administration: Prepare a fresh solution of ICG in sterile saline (or 5% glucose) at a concentration of 0.5-1.0 mg/mL. Filter through a 0.2 μm syringe filter.
• Injection: Cannulate the tail vein. Inject ICG as a bolus at a dose of 2-3 mg/kg (approx. 100-150 μL for a 25g mouse).
• Imaging Setup:
  • Power on the 808 nm laser diode and allow it to stabilize.
  • Position the anesthetized animal under the laser beam. Ensure even illumination of the region of interest (ROI).
  • Place the NIR-II optimized InGaAs or 2D InGaAs camera, equipped with a series of long-pass filters (LP 1000 nm, LP 1200 nm, LP 1500 nm), to collect emitted light.
  • Set camera acquisition parameters: exposure time (50-200 ms), frame rate (5-20 Hz), and binning.
• Data Acquisition:
  • Acquire a background image prior to ICG injection.
  • Initiate continuous imaging immediately before and during injection. Capture the first-pass circulation for ~30-60 seconds.
  • Continue imaging for up to 20-30 minutes to monitor ICG distribution and clearance.
  • For multi-window imaging, sequentially switch the emission filters (e.g., 1000LP, 1200LP, 1500LP) at designated time points.
• Image Processing & Analysis:
  • Subtract the background image from all subsequent frames.
  • Apply a Gaussian blur or median filter to reduce noise if necessary.
  • Calculate SBR as (Mean Signal in ROI - Mean Background) / Standard Deviation of Background.
  • Measure Full Width at Half Maximum (FWHM) of intensity profiles across visible vessels to quantify spatial resolution.

Protocol 2: Comparative NIR-I / NIR-II Tumor Margin Delineation

Objective: To compare the efficacy of ICG for defining orthotopic tumor margins in the NIR-I and NIR-II windows.

Procedure:

• Tumor Model: Establish a subcutaneous or orthotopic tumor model (e.g., 4T1 breast carcinoma in the mammary fat pad).
• Imaging Time Point: Image when tumors reach 5-8 mm in diameter.
• Dual-Modality Imaging:
  • Administer ICG intravenously (as in Protocol 1). Wait 24 hours for optimal clearance from circulation and accumulation in tumors via the Enhanced Permeability and Retention (EPR) effect.
  • NIR-I Acquisition: Using a standard NIR-I imaging system (CCD camera with 800-850 nm filter), acquire fluorescence images of the tumor.
  • NIR-II Acquisition: Without moving the animal, switch to the NIR-II imaging system (808 nm excitation, 1250 nm long-pass emission filter) and acquire images of the same FOV.
• Analysis:
  • Coregister NIR-I and NIR-II images.
  • Manually or algorithmically define the tumor boundary based on the fluorescence signal in each window.
  • Compare the defined margin to the anatomical boundary confirmed post-resection/ex vivo. Quantify metrics such as Dice coefficient, precision, and recall.

Visualizations

NIR-I vs NIR-II Tissue Interaction

NIR-II Imaging Experimental Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for NIR-II Imaging with ICG

Item	Function & Description	Example/Note
ICG (Indocyanine Green)	FDA-approved NIR fluorophore. Primary peak at ~800 nm (NIR-I) with a long tail extending into NIR-II (>1000 nm). Used for vascular imaging, tumor labeling, and perfusion assessment.	Lyophilized powder, reconstituted in aqueous solvent. Light and temperature sensitive.
808 nm Laser Diode	Excitation source. Matches ICG's peak excitation, efficiently pumping molecules for NIR-II tail emission. Must be stable and have appropriate power output (e.g., 0.1-0.5 W/cm²).	Continuous wave (CW) laser with fiber optic output for uniform illumination.
InGaAs Camera (1D or 2D)	NIR-II photon detection. Essential for capturing light >1000 nm. 1D for spectroscopy, 2D for imaging. Requires cooling to reduce dark noise.	Teledyne Princeton Instruments, Hamamatsu, or Sylvac. Cooled to -80°C.
Long-Pass (LP) Emission Filters	Spectral selection. Isolates the desired NIR-II window by blocking laser light and shorter wavelengths. Critical for SBR.	e.g., LP1000, LP1200, LP1300, LP1500 nm. OD >5 at blocking range.
Small Animal Imaging Stage	Animal positioning. Heated stage with anesthesia manifold to maintain physiological conditions and immobilize the subject during long acquisitions.	Kent Scientific, Bruker, etc.
Image Analysis Software	Data quantification. For background subtraction, SBR calculation, resolution measurement (FWHM), and kinetic analysis.	ImageJ/FIJI, Living Image, MATLAB, or vendor-specific software.

Indocyanine green (ICG) is a near-infrared (NIR) fluorophore first approved by the FDA in 1959 for hepatic function diagnostics. Its recent resurgence is driven by applications in intraoperative imaging and, more significantly, its role as a benchmark agent for the emerging field of NIR-II (1000-1700 nm) imaging. Within the context of advancing clinical translation research for NIR-II imaging, ICG's "tail emission" beyond 1000 nm, though weak, provides a critical bridge for protocol development and technology validation. This article revisits ICG's fundamental properties, pharmacokinetics, and regulatory status, providing essential application notes and protocols for researchers aiming to leverage its unique characteristics for next-generation bioimaging.

Chemistry & Optical Properties

ICG (C43H47N2NaO6S2) is a water-soluble, anionic tricarbocyanine dye with a molecular weight of 774.96 Da.

Key Chemical & Optical Properties Table

Property	Specification / Value	Notes for NIR-II Research
Empirical Formula	C₄₃H₄₇N₂NaO₆S₂	Anionic character affects protein binding.
Primary Excitation (λ_ex)	~780-810 nm	Standard laser diode sources are suitable.
Primary Emission (λ_em)	~820-850 nm (Peak)	Corresponds to traditional NIR-I window.
NIR-II Tail Emission	Extends to ~1300 nm	Low quantum yield but usable with sensitive NIR-II detectors.
Quantum Yield (PBS)	~0.002-0.004 (NIR-II)	Highly environment-dependent; increases in plasma.
Molar Extinction Coefficient	~1.3 x 10⁵ M⁻¹cm⁻¹ (in plasma)	High absorbance enables low-dose imaging.
Solubility	Aqueous (hydrophilic)	Aggregates in aqueous solutions; requires reconstitution per protocol.

Diagram Title: ICG Molecular Structure & Emission Profile

Pharmacokinetics & Biodistribution

ICG exhibits rapid and predictable pharmacokinetics (PK) upon intravenous injection, primarily dictated by its high plasma protein binding.

ICG Pharmacokinetics Summary Table

Parameter	Typical Value / Profile	Clinical & Research Implication
Plasma Protein Binding	>95% binds to albumin & lipoproteins.	Confined to vascular compartment; defines initial distribution volume.
Plasma Half-Life (t½)	2-4 minutes in healthy adults.	Requires rapid imaging protocols post-injection.
Clearance Pathway	Exclusive hepatic uptake > biliary excretion.	Liver and bile duct imaging is highly efficient.
Renal Clearance	Negligible (<0.1%).	Not suitable for renal function imaging.
Volume of Distribution	Approximates plasma volume (~3-5 L).	Serves as a vascular flow and perfusion tracer.
Metabolism	No systemic metabolism; excreted unchanged.	Stable fluorescent signal, no metabolic byproducts.

Diagram Title: ICG In Vivo Pathway Post-IV Injection

Clinical Approval Status & NIR-II Context

ICG holds broad clinical approvals, primarily as a diagnostic agent. Its use as an imaging agent in surgery is often "off-label" but standard of care.

ICG Clinical & Regulatory Status Table

Region / Agency	Approval Status & Indications	Relevance to NIR-II Imaging Research
U.S. FDA	Approved (1959): Determining cardiac output, hepatic function, liver blood flow, and for ophthalmic angiography.	The established safety profile facilitates IRB approval for pilot NIR-II imaging studies.
EMA (Europe)	Approved: Similar cardiovascular and hepatic diagnostic indications.	Enables European clinical trials for NIR-II imaging extensions.
PMDA (Japan)	Approved; widely used in gastrointestinal and cancer surgery.	Large clinical experience supports translational research protocols.
NMPA (China)	Approved.	Active center for clinical NIR-II imaging research using ICG.
Common Off-Label Uses	Sentinel lymph node mapping, tumor visualization, perfusion assessment in reconstructive surgery.	These surgical applications are direct gateways for implementing NIR-II imaging systems.

Application Notes & Protocols for NIR-II Research

Protocol: Reconstitution and Preparation of ICG for In Vivo NIR-II Imaging

Objective: To prepare a stable, sterile ICG solution for intravenous administration in animal models or human studies. Materials: See "Scientist's Toolkit" below. Procedure:

• Aseptic Setup: Perform all steps in a laminar flow hood using sterile technique.
• Reconstitution: Using a sterile syringe, draw 10 mL of Sterile Water for Injection (USP). Slowly inject the water into the vial containing 25 mg of ICG lyophilized powder. Avoid forceful injection.
• Gentle Mixing: Gently swirl or roll the vial until the powder is completely dissolved. DO NOT SHAKE. This minimizes foam formation and protects the dye structure.
• Dilution: For most NIR-II imaging applications, further dilute the stock solution (2.5 mg/mL) with 0.9% Sodium Chloride Injection (Normal Saline) to the desired working concentration (e.g., 0.025-0.5 mg/mL for mice, 0.1-0.5 mg/kg for human equivalent).
• Immediate Use: Administer the prepared solution within 6 hours of reconstitution. Protect from light by wrapping the syringe or vial in aluminum foil until use.
• Administration: Inject via a pre-established intravenous line as a rapid bolus, followed by a saline flush.

Protocol: Dynamic NIR-II Angiography in a Rodent Model

Objective: To capture real-time vascular flow and perfusion using ICG's NIR-II tail emission. Materials: See "Scientist's Toolkit" below. Procedure:

• Animal Preparation: Anesthetize and position the animal (e.g., mouse) on a heating pad on the imaging stage. Secure catheter lines (for injection and fluids).
• System Calibration: Power on the NIR-II imaging system (e.g., InGaAs camera with 808 nm laser excitation). Set acquisition parameters: exposure time (50-200 ms), frame rate (5-10 fps), laser power (<100 mW/cm²). Apply a 1000 nm long-pass emission filter.
• Background Acquisition: Record a 10-second pre-injection video to establish tissue autofluorescence and system noise baseline.
• ICG Administration: As acquisition continues, rapidly inject the pre-prepared ICG bolus (e.g., 0.1 mg/kg in 100 µL saline) via the tail vein catheter.
• Data Acquisition: Record continuously for 3-5 minutes post-injection to capture the first-pass arterial phase, capillary perfusion, and venous clearance phases.
• Data Analysis: Use region-of-interest (ROI) analysis on major vessels and tissues to generate time-intensity curves. Calculate parameters like time-to-peak, wash-in/wash-out rates, and relative perfusion indices.

Protocol: Sentinel Lymph Node (SLN) Mapping Simulation Ex Vivo

Objective: To demonstrate the principle of ICG-based lymphatic mapping for NIR-II system validation. Materials: Excised tissue block (containing tumor and draining basin), ICG solution, NIR-II imaging system. Procedure:

• Tissue Preparation: Acquire fresh, unfixed tissue specimen. Identify the presumed tumor injection site.
• ICG Injection (Simulated): Using a fine-gauge needle, inject 10-20 µL of ICG solution (0.05 mg/mL) intradermally or peritumorally in the specimen at the simulated primary site.
• Incubation: Allow the specimen to rest for 5-15 minutes at room temperature to permit lymphatic uptake and flow.
• NIR-II Imaging: Place the specimen under the NIR-II imager. Use 808 nm excitation and a 1000 nm LP filter.
• Identification: Identify the draining lymphatic channel(s) as bright, linear structures. Trace them to the first (sentinel) node(s) that become fluorescent.
• Excision Guidance: Use the NIR-II overlay to guide the precise excision of the fluorescent SLN for further pathological analysis.

The Scientist's Toolkit

Essential Research Reagent Solutions & Materials

Item	Function / Purpose	Key Consideration for NIR-II
ICG Lyophilized Powder	The active fluorophore.	Ensure high purity (>95%) from a reliable supplier (e.g., Pulsion, Diagnostic Green). Lot variability can affect signal.
Sterile Water for Injection (USP)	For initial reconstitution.	Must be aqueous, without preservatives that might quench fluorescence.
0.9% Sodium Chloride (Normal Saline)	For dilution and IV flush.	Standard carrier fluid compatible with ICG.
InGaAs NIR-II Camera	Detects photons >1000 nm.	Requires cooling, high sensitivity. Models from Princeton Instruments, NIRvana, or custom-built.
808 nm Laser Diode	Optimal excitation source for ICG.	Must be coupled with appropriate bandpass filter (e.g., 785/40 nm).
1000 nm Long-Pass Emission Filter	Isolates NIR-II "tail" emission.	Critical to block NIR-I signal and laser scatter. Quality dictates signal-to-noise.
Sterile Syringes & Catheters	For precise ICG administration.	Use low-adsorption syringes; plastic may bind ICG.
Data Acquisition Software	Controls camera & laser, records video.	Should allow real-time display and ROI analysis (e.g., LabVIEW, MATLAB, vendor software).

Diagram Title: NIR-II Imaging Workflow with ICG

ICG remains an indispensable tool in the transition from NIR-I to NIR-II clinical imaging. Its well-defined chemistry, rapid and predictable pharmacokinetics, and extensive clinical safety profile lower the barrier for translational research. While its NIR-II quantum yield is low, optimized protocols and sensitive InGaAs cameras enable robust angiography, lymphatic mapping, and tumor perfusion studies. As such, mastering ICG-based protocols is a fundamental step for any research team aiming to translate novel NIR-II fluorophores and imaging systems into clinical practice.

Indocyanine green (ICG) tail emission refers to the prolonged fluorescence signal observed in the second near-infrared window (NIR-II, 1000-1700 nm) after the initial NIR-I (700-900 nm) fluorescence decays. This phenomenon is crucial for advancing deep-tissue, high-resolution biomedical imaging. This Application Note details the photophysical mechanisms and provides standardized protocols for exploiting ICG's NIR-II tail emission for clinical translation research.

Photophysical Mechanism and Quantitative Data

The NIR-II emission from ICG is attributed to the formation of aggregates and/or photo-degradation products following intravenous administration and laser excitation.

Table 1: Key Photophysical Properties of ICG in NIR-I vs. NIR-II Emission

Property	NIR-I Emission (Peak ~820 nm)	NIR-II Tail Emission (>1000 nm)	Measurement Conditions
Primary Source	Monomeric ICG molecules	ICG aggregates & photo-products	In serum or PBS, 37°C
Fluorescence QY	~0.5-1.3% (in water)	~0.1-0.3% (estimated)	Exc: ~780 nm
Lifetime	~0.3-0.6 ns	Several ns to μs (long-lived component)	Time-correlated single-photon counting
Optimal Excitation	~780-800 nm	~808 nm	Continuous-wave or pulsed laser
Peak Emission	~820-830 nm	Broadband, 1000-1300 nm	Recorded with InGaAs detector

Table 2: Factors Influencing ICG NIR-II Tail Emission Intensity

Factor	Effect on NIR-II Signal	Rationale
ICG Concentration	Non-linear increase, peaks at ~100-500 μM in serum	Enhanced aggregate formation at optimal concentrations.
Incubation in Serum	Significant signal increase (>5x vs. PBS)	Protein binding (e.g., albumin) stabilizes H-aggregates.
Excitation Power	Increases sub-linearly; saturates at high power	Photobleaching of monomers vs. generation of emissive products.
Time Post-Injection (in vivo)	Peak NIR-II signal at ~24-48 hrs post-IV	Slow clearance and accumulation in reticuloendothelial system.

Experimental Protocols

Protocol 1: In Vitro Characterization of ICG NIR-II Tail Emission

Objective: To prepare and measure the NIR-II fluorescence spectrum of ICG aggregates in a biologically relevant matrix. Materials:

• ICG powder (lyophilized, sterile).
• Bovine Serum Albumin (BSA, Fraction V) or Fetal Bovine Serum (FBS).
• Phosphate-Buffered Saline (PBS), pH 7.4.
• 808 nm continuous-wave laser diode.
• Spectrophotometer (UV-Vis-NIR).
• NIR-II spectrometer with cooled InGaAs array detector (1000-1700 nm range).
• Quartz cuvettes.

Procedure:

• Sample Preparation: Prepare a 1 mM stock solution of ICG in DMSO. Immediately dilute this stock in PBS containing 10% (w/v) BSA (or 50% FBS) to final ICG concentrations of 10 μM, 100 μM, and 500 μM. Vortex gently.
• Incubation: Incubate samples at 37°C in the dark for 24 hours to allow aggregate formation.
• Absorbance Measurement: Use a spectrophotometer to record absorption spectra (600-900 nm) of each sample. Note the characteristic shift from ~780 nm (monomer) to ~700 nm (H-aggregate).
• NIR-II Fluorescence Measurement:
  • Set the 808 nm laser to a safe power level (e.g., 50 mW/cm²). Use appropriate laser safety goggles.
  • Place the sample in a quartz cuvette in the spectrometer.
  • Use a 1000 nm long-pass filter between the sample and detector to block NIR-I light.
  • Acquire the fluorescence spectrum from 1000 to 1600 nm. Integrate signal for 1-5 seconds.
  • Repeat for all concentrations and a blank (BSA/PBS without ICG).
• Data Analysis: Subtract the blank spectrum. Plot intensity vs. wavelength. Compare the integrated NIR-II signal (1100-1500 nm) across concentrations.

Protocol 2: In Vivo NIR-II Imaging Using ICG Tail Emission

Objective: To perform non-invasive, deep-tissue imaging in a rodent model using the long-term NIR-II signal from ICG. Materials:

• Animal model (e.g., nude mouse) with approved IACUC protocol.
• ICG solution for injection (sterile, in saline, 0.5-1 mg/mL).
• Isoflurane anesthesia system.
• 808 nm laser for excitation (power density <0.3 W/cm² on skin).
• NIR-II imaging system with cooled InGaAs camera (e.g., Princeton Instruments NIRvana).
• Set of 1000 nm, 1100 nm, 1250 nm, and 1350 nm long-pass emission filters.

Procedure:

• Animal Preparation: Anesthetize the mouse with 2% isoflurane in oxygen. Place the animal in a prone position on a warming stage. Apply ophthalmic ointment.
• Pre-Injection Baseline: Acquire a baseline NIR-II image using 808 nm excitation and a 1000 nm LP filter. Set exposure time (e.g., 100-500 ms).
• ICG Administration: Inject ICG via tail vein at a dose of 2-5 mg/kg. Flush with saline.
• Time-Course Imaging: Acquire sequential images at the following time points: 1 min, 5 min, 30 min, 2 h, 24 h, and 48 h post-injection.
  • For each time point, acquire images using different emission filters (1000LP, 1100LP, etc.) to assess spectral evolution.
  • Maintain consistent laser power, camera settings, and animal positioning.
• Image Analysis:
  • Use software (e.g., ImageJ, Living Image) to draw regions of interest (ROIs) over target tissues (liver, tumor) and a background region.
  • Calculate signal-to-background ratio (SBR) as: SBR = (Mean Signal_ROI - Mean Signal_Background) / Standard Deviation_Background.
  • Plot SBR vs. time for each tissue and filter.

Diagram: ICG NIR-II Emission Mechanism & Workflow

Diagram Title: ICG NIR-II Photophysics and Imaging Workflow (92 chars)

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for ICG NIR-II Tail Emission Studies

Item	Function & Relevance	Example/Specification
ICG (Clinical Grade)	The FDA-approved fluorophore; source of tail emission. Must be pure and stored desiccated in the dark.	PULSION (Diagnostic Green), Sigma-Aldrich I2633.
Albumin (BSA or HSA)	Critical for stabilizing ICG H-aggregates in vitro, mimicking the in vivo serum environment.	Fatty-acid free BSA, Fraction V.
NIR-II Spectrometer	Measures the weak, broad NIR-II emission spectrum. Requires sensitivity in 1000-1700 nm range.	Princeton Instruments NIRvana with InGaAs array.
Cooled InGaAs Camera	Essential for in vivo imaging; high quantum efficiency and low noise in NIR-II.	Teledyne Princeton Instruments, NIRvana 640ST.
808 nm Laser Diode	Optimal excitation source for both ICG monomer and aggregates.	Continuous-wave, power-adjustable, fiber-coupled.
Long-Pass Filters	Blocks residual NIR-I and laser light, allowing only NIR-II signal to reach the detector.	1000 nm, 1100 nm, 1250 nm LP filters (Thorlabs, Semrock).
Animal Model	For translational research, evaluating biodistribution and long-term imaging potential.	Nude mice (for tumor models), C57BL/6 (for vascular studies).
Image Analysis Software	For quantifying signal-to-background ratio, biodistribution, and creating time-course plots.	ImageJ/FIJI, Living Image (PerkinElmer), MATLAB.

Advancements in clinical translation research for in vivo imaging are increasingly focused on the second near-infrared (NIR-II, 1000-1700 nm) window. A central thesis posits that leveraging the tail emission of the clinically approved dye Indocyanine Green (ICG) in the NIR-II window offers a uniquely translatable path for deep-tissue, high-resolution imaging. This application note details the critical spectral properties—Emission Peak, Quantum Yield (QY), and Brightness—that define probe performance within this paradigm, providing protocols for their quantification to accelerate the development of NIR-II imaging agents for drug development and clinical research.

Core Spectral Properties: Definitions & Quantitative Data

The efficacy of an NIR-II fluorophore is governed by three interdependent properties. Data for representative agents, including ICG and novel probes, are summarized below.

Table 1: Key Spectral Properties of Selected NIR-II Fluorophores

Fluorophore	Emission Peak (nm)	Quantum Yield (QY, %) in NIR-II*	Molar Extinction Coefficient (ε, M⁻¹cm⁻¹)	Brightness (ε × QY)	Primary Application Context
ICG (in serum)	~820 (tail >1000)	0.1-0.5% (>1000 nm)	~1.2 × 10⁵ (at 780 nm)	~120-600	Clinical benchmark, vascular imaging
IR-26 (reference)	~1200	0.05% (in DCE)	1.0 × 10⁴	~5	Absolute QY reference standard
CH1055-PEG	~1055	0.3-0.8%	1.1 × 10⁵	~330-880	Targeted molecular imaging
Ag₂S Quantum Dots	1050-1350	2.1-15.8%	~1.5 × 10⁴	~315-2370	High-contrast bioimaging
Lanthanide Nanoparticles	1525 (Er³⁺)	~0.1-1.0%	~(low)	N/A	Multiplexed imaging

Note: QY in the NIR-II window is typically measured relative to a standard like IR-26 and is highly dependent on the local environment (solvent, matrix, temperature).

Experimental Protocols

Protocol 3.1: Measuring Absolute Quantum Yield in the NIR-II Window

Objective: Determine the absolute photoluminescence quantum yield of a fluorophore emitting in the NIR-II region (1000-1700 nm).

Materials:

• Integrating sphere (e.g., Labsphere) coupled to a NIR-spectrometer (InGaAs detector).
• Calibrated NIR-II light source (e.g., 808 nm or 980 nm laser).
• Standard reference: IR-26 dye in 1,2-dichloroethane (DCE, QY = 0.05%).
• Sample: Fluorophore in desired buffer/matrix (e.g., ICG in 1% PBS/BSA).
• Quartz cuvettes.

Procedure:

• System Setup: Connect the integrating sphere to the NIR spectrometer. Ensure the laser excitation port is at 90° to the emission port.
• Background Measurement: Place a cuvette with pure solvent/buffer in the sphere. Record the emission spectrum (E_scat(λ)) with laser excitation.
• Sample Measurement: Replace with the fluorophore sample. Record the emission spectrum (E_sample(λ)).
• Reference Measurement: Replace with the IR-26/DCE reference standard. Record the emission spectrum (E_ref(λ)).
• Calculation: Use the equation: Φ_sample = Φ_ref × (I_sample / I_ref) × (A_ref / A_sample) × (η_sample² / η_ref²) where Φ is QY, I is the integrated emission intensity (corrected for background scatter), A is absorbance at excitation wavelength, and η is refractive index of the solvent.
• NIR-II Specific: Integrate intensities only over the spectral range of interest (e.g., 1000-1400 nm) to calculate the NIR-II-specific QY.

Protocol 3.2: Determining Relative Brightness for In Vitro Comparison

Objective: Compare the practical brightness of different probes under standardized conditions relevant to biological imaging.

Materials:

• Plate reader or fluorometer with NIR-II capable detector.
• Black-walled 96-well plates.
• Serial dilution of fluorophores (ICG, experimental probes) in imaging buffer.
• Microplate reader software.

Procedure:

• Absorbance Measurement: Prepare a dilution series (e.g., 0.1-10 µM) of each fluorophore. Measure absorbance at the planned excitation wavelength (e.g., 808 nm). Plot absorbance vs. concentration to verify linearity and determine exact concentration.
• Emission Measurement: Using the same plate, measure the integrated emission intensity in the NIR-II channel (e.g., >1000 nm long-pass filter) for each well.
• Background Subtraction: Subtract the intensity of a buffer-only well.
• Brightness Calculation: For each probe, plot fluorescence intensity vs. concentration. The slope of the linear region is proportional to brightness (ε × Φ). Normalize all slopes to a control (e.g., ICG in same buffer) to report relative brightness.

Protocol 3.3: In Vivo NIR-II Imaging Using ICG Tail Emission

Objective: Acquire high-resolution vascular images in a murine model using the NIR-II tail emission of ICG.

Materials:

• NIR-II imaging system (e.g., Princeton Instruments with InGaAs camera, 808 nm laser).
• Anesthetized mouse model.
• ICG solution (100 µL of 200 µM in saline).
• Heating pad.
• Imaging software (e.g., LightField, MATLAB).

Procedure:

• System Calibration: Power on the NIR-II system and cool the camera. Set excitation laser to 808 nm at a safe power density (<100 mW/cm²). Set emission collection with a 1000 nm or 1100 nm long-pass filter.
• Animal Preparation: Anesthetize the mouse and place it prone on the heated stage. Position for desired field of view (e.g., hindlimb vasculature).
• Background Image: Acquire a pre-injection image (exposure time: 50-200 ms).
• ICG Injection: Administer ICG via tail vein or retro-orbital injection.
• Image Acquisition: Start continuous acquisition immediately post-injection. Capture the first-pass dynamic sequence (high frame rate: 5-10 fps for 60s), then periodic static images for up to 30 minutes to monitor clearance.
• Image Processing: Subtract the background image. Apply a linear contrast adjustment to the dynamic range. Generate time-intensity curves for regions of interest (e.g., artery vs. vein).

Visualization: Pathways and Workflows

Diagram Title: Thesis Framework: ICG Tail Emission to NIR-II Clinical Translation

Diagram Title: Protocol: Absolute NIR-II Quantum Yield Measurement

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Spectral Characterization & Imaging

Item	Function/Description	Example Product/Catalog
NIR-II Fluorophore: ICG	Clinically approved benchmark; source of tail emission >1000 nm for foundational studies.	Sigma-Aldrich, I2633 (for research)
Quantum Yield Standard: IR-26 Dye	Absolute QY reference (0.05% in DCE) for calibrating NIR-II measurements.	FEW Chemicals, IR-26
Integrating Sphere	Essential accessory for accurate absolute photoluminescence quantum yield measurements.	Labsphere, 4P-GPS-053-SL
NIR-II Sensitive Spectrometer	Detects weak emissions in 900-1700 nm range. Requires InGaAs array.	Princeton Instruments, NIRvana HS
Long-Pass Emission Filters	Isolates NIR-II signal; blocks excitation laser and shorter wavelengths.	Thorlabs, FELH1000 / FELH1100
Biological Matrix (BSA/PBS)	Mimics physiological environment for measuring ICG/probe properties (QY, stability).	MilliporeSigma, A7906 (BSA)
In Vivo Imaging System	Complete setup for rodent NIR-II imaging: laser, cooled InGaAs camera, filters.	Bruker, In-Vivo Xtreme II
Anesthetic	For humane restraint of animal models during in vivo imaging procedures.	Zoetis, Isoflurane, USP

Historical Context and Evolution from NIR-I to NIR-II Imaging with ICG

Near-infrared (NIR) fluorescence imaging has undergone a significant evolution, driven by the pursuit of deeper tissue penetration and higher spatial resolution. The field originated with NIR-I imaging (700–900 nm), where Indocyanine Green (ICG) emerged as a dominant clinical fluorophore following its FDA approval in 1959. ICG's initial applications were in ophthalmology and hepatic function assessment. Its utility in NIR-I fluorescence imaging expanded in the 1990s-2000s for sentinel lymph node mapping, angiography, and tumor visualization.

The limitations of NIR-I, including tissue autofluorescence, photon scattering, and absorption, prompted exploration of the second NIR window (NIR-II, 1000–1700 nm). Research over the past decade revealed that ICG, traditionally a NIR-I dye (peak emission ~820 nm), possesses a non-negligible "tail emission" in the NIR-II region (>1000 nm) when administered at high doses. This discovery provided a clinically translatable bridge into NIR-II imaging, leveraging an already approved agent. The evolution represents a paradigm shift from developing entirely new NIR-II fluorophores to repurposing and optimizing the use of ICG for superior imaging performance.

Comparative Quantitative Data: NIR-I vs. NIR-II with ICG

Table 1: Performance Metrics of ICG in NIR-I vs. NIR-II Windows

Metric	NIR-I (800-900 nm)	NIR-II (1000-1300 nm)	Improvement Factor
Tissue Penetration Depth	1-3 mm (in muscle)	5-8 mm (in muscle)	~2.5x
Spatial Resolution (FWHM)	~2-3 mm at 5 mm depth	~0.5-1 mm at 5 mm depth	~3x
Signal-to-Background Ratio (SBR)*	2-5	5-15	2-5x
Optimal ICG Dose (for imaging)	0.1-0.3 mg/kg	2-5 mg/kg	10-20x
Tissue Autofluorescence	Moderate-High	Very Low	Significant reduction
Typical Frame Rate	10-30 fps	5-10 fps	Lower (due to detector sensitivity)

*SBR in model tumor imaging studies.

Table 2: Key Milestones in the Evolution of ICG Imaging

Year	Milestone	Significance
1959	FDA approves ICG for medical diagnostics.	Foundation for clinical translation.
1990s	ICG used for sentinel lymph node biopsy (NIR-I).	Established intraoperative fluorescence imaging.
2009	First demonstration of NIR-II imaging with nanotubes.	Opened the NIR-II biological imaging field.
2015-2016	Rediscovery of ICG's NIR-II tail emission.	Bridged clinical agent with advanced imaging modality.
2019-2022	Clinical pilot studies of ICG NIR-II for vasculature & tumor surgery.	Demonstrated human translation feasibility.
2023-Present	Optimization of ICG formulations & dose for NIR-II.	Focus on protocol standardization for research/clinical use.

Application Notes and Experimental Protocols

Protocol: ICG Preparation for NIR-II Imaging

Aim: To prepare a stable, sterile ICG solution optimized for NIR-II tail emission imaging. Materials: See Scientist's Toolkit. Procedure:

• Reconstitution: Reconstitute lyophilized ICG powder with sterile water for injection (WFI) or 5% dextrose solution to a stock concentration of 2.5 mg/mL. Avoid saline, which promotes aggregation.
• Filtration: Immediately filter the solution through a 0.2 µm sterile syringe filter to remove insoluble aggregates.
• Dilution: Dilute the filtered stock to the desired concentration (typically 0.5-1.0 mg/mL for injection) using WFI or dextrose. Prepare fresh for each experiment; do not store diluted solutions >4 hours.
• Quality Check: Visually inspect for any precipitate. Measure absorbance at ~780 nm (in PBS) to confirm concentration (ε ~ 130,000 M⁻¹cm⁻¹).

Protocol: In Vivo NIR-II Imaging of Tumor Vasculature with ICG Tail Emission

Aim: To visualize tumor vasculature architecture with high resolution using ICG. Animal Model: Mouse with subcutaneously implanted tumor (e.g., 4T1, U87MG). Imaging System: Requires a NIR-II-capable setup: 808 nm laser for excitation, 1000 nm long-pass emission filters, and an InGaAs or cooled Si-CCD camera for NIR-II detection.

Procedure:

• Animal Preparation: Anesthetize mouse using isoflurane (2-3% induction, 1-2% maintenance). Place animal in prone position on heated stage.
• Baseline Imaging: Acquire a pre-injection NIR-II image (exposure: 100-300 ms, laser power: 50-100 mW/cm²) to record background.
• ICG Administration: Inject ICG solution via tail vein at a dose of 2.5-5.0 mg/kg (bolus, 100 µL volume). Start image acquisition immediately.
• Dynamic Imaging: Record images continuously at 2-5 frames per second for the first 3 minutes (vascular phase).
• High-Resolution Imaging: At 5-10 minutes post-injection, acquire high signal-to-noise ratio static images (exposure: 500-1000 ms) for detailed vascular mapping.
• Data Analysis: Use software (e.g., ImageJ, Living Image) to analyze Signal-to-Background Ratio (SBR), vessel width, and perfusion kinetics.

Protocol: Sentinel Lymph Node Mapping in NIR-II

Aim: To map lymphatic flow and identify sentinel lymph node(s). Procedure:

• ICG Injection: Intradermally inject 10-20 µL of ICG solution (0.5-1.0 mg/mL) at the site of interest (e.g., paw, peritumoral).
• Dynamic Imaging: Begin continuous NIR-II imaging immediately. Observe the lymphatic channels draining the injection site.
• Node Identification: The first, brightly fluorescent node along the channel is the sentinel lymph node. This typically appears within 1-3 minutes.
• Guidance: This protocol can be used to guide surgical excision, with the NIR-II signal providing deeper, clearer visualization than NIR-I.

Visualization: Logical Workflows and Pathways

Title: Evolution from NIR-I to NIR-II Imaging with ICG

Title: ICG NIR-I and NIR-II Imaging Workflow

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Reagents and Materials for ICG NIR-II Imaging Research

Item	Function/Description	Key Consideration for NIR-II
ICG (Lyophilized Powder)	The fluorophore. Provides both NIR-I peak and NIR-II tail emission.	Use pharmaceutical grade. High purity (>95%) minimizes contaminants.
Sterile Water for Injection (WFI) / 5% Dextrose	Reconstitution and dilution solvent.	Prefer dextrose over saline to prevent ICG aggregation and quenching.
0.2 µm Syringe Filter	Removes insoluble aggregates from ICG solution.	Critical for NIR-II to reduce light scattering from particles.
NIR-II Imaging System	InGaAs camera or deep-cooled Si-CCD, 808 nm laser, 1000-1400 nm bandpass/longpass filters.	Sensitivity > 1000 nm and low noise are essential for detecting weak tail emission.
Animal Model (e.g., Mouse)	In vivo model for translational research.	Hair removal (shaving/cream) is necessary to reduce photon scattering.
Isoflurane/Oxygen Anesthesia System	For humane animal immobilization during imaging.	Stable anesthesia is vital for motion-free, high-resolution imaging.
Image Analysis Software (e.g., ImageJ, LI-COR)	For quantifying signal intensity, SBR, vessel dimensions, and kinetics.	Must support 16-bit TIFF images from InGaAs cameras.
Black Imaging Chamber	Enclosed stage to exclude ambient light.	Minimizes background noise, crucial for low-light NIR-II detection.

From Bench to Bedside: Protocols and Real-World Applications of ICG NIR-II Imaging

This application note outlines the essential components and protocols for configuring an imaging system optimized for NIR-II imaging with Indocyanine Green (ICG) tail emission, a critical modality for clinical translation research. ICG, an FDA-approved dye, exhibits a characteristic "tail" emission in the NIR-II window (1000-1300 nm) when excited at ~800 nm. Imaging in this spectral region offers superior tissue penetration, reduced scattering, and minimal autofluorescence compared to traditional NIR-I fluorescence, enabling deeper, higher-resolution in vivo visualization of vasculature, tumors, and lymphatic drainage.

Core System Components & Quantitative Specifications

Cameras for NIR-II Detection

Critical Requirement: High quantum efficiency (QE) in the 1000-1350 nm range. Silicon-based detectors are insensitive beyond ~1000 nm; thus, specialized sensors are mandatory.

Table 1: Comparison of NIR-II Camera Technologies

Camera Type	Sensor Material	Typical QE @ 1100 nm	Cooling Method	Key Advantage	Key Limitation	Example Models
InGaAs FPA	Indium Gallium Arsenide	60-85%	Thermoelectric (TE) or Stirling	High sensitivity, fast frame rates	Small arrays (e.g., 640x512), high cost	Teledyne FLIR A6700, Sensors Unlimited SU1024
Extended InGaAs	Extended Range InGaAs	40-60% @ 1300 nm	TE or Stirling	Sensitivity to 1600-2200 nm	Higher dark current, lower QE than standard InGaAs	Princeton Instruments OMA V:2D-XR, Xenics Cheetah-640CL-XR
sCMOS (with Converter)	Silicon (with Upconversion)	~5-10% (System dependent)	TE	Leverages visible sCMOS resolution & speed	Very low system efficiency, complex optical path	Not a standard commercial solution.

Recommendation for ICG: A standard InGaAs focal plane array (FPA) camera (900-1700 nm range) is optimal, balancing cost, sensitivity, and availability. Cooling to -40°C or below is essential to minimize dark noise during long exposures common in biodistribution studies.

Critical Requirement: Stable, narrow-band output matching the ICG excitation peak (~780-810 nm). Power must be calibrated for safe in vivo use.

Table 2: Excitation Source Options

Source Type	Wavelength (nm)	Typical Output Power	Beam Profile	Modulation Capability	Best For
Continuous Wave (CW) Laser Diode	785, 808, 830	50 mW - 2 W	Elliptical, requires collimation	External chopper or driver required	Standard fluorescence, cost-effective setup.
Modulated Laser Diode System	808	100-500 mW	Fiber-coupled, circular	Direct TTL modulation (kHz-MHz)	Fluorescence lifetime imaging (FLI), gating for scatter reduction.
Tunable Ti:Sapphire Laser	700-1000	>1 W	Gaussian, excellent	Yes	Multiplexing with other dyes, precise wavelength matching.

Recommendation: A fiber-coupled 808 nm CW laser diode with a dedicated driver permitting analog/TTL modulation provides flexibility for future FLI applications. Power at the sample must be measured with a photodiode power meter.

Optical Filters

Critical Requirement: Precise spectral selection to isolate the weak ICG tail emission from the intense excitation light and any NIR-I fluorescence (<900 nm).

Table 3: Essential Filter Set for ICG NIR-II Imaging

Filter Type	Position	Specification Example	Function
Excitation Bandpass	Before sample	785/50 nm or 808/10 nm	Cleans laser line, removes pump diode spontaneous emission.
Beam Splitter or Dichroic Mirror	After sample, before camera	850 nm or 900 nm Longpass Edge	Reflects excitation light to source, transmits NIR-I & NIR-II emission to camera.
Emission Filter (Critical)	Before camera sensor	1000 nm Longpass or 1250/50 nm Bandpass	Blocks residual NIR-I fluorescence (<1000 nm) and collects the specific ICG NIR-II tail emission. A 1000 nm LP is common for initial studies; a bandpass (e.g., 1250/50) improves specificity.
Additional Shortpass	Before camera (optional)	1300 nm Shortpass	Blocks light >1300 nm to reduce thermal background noise on some InGaAs sensors.

Vendor Note: High-performance NIR filters are available from Chroma Technology, Semrock (IDEX), Omega Optical, and Thorlabs.

Safety Standards and Best Practices

Safe operation integrates laser safety, biological safety, and electrical safety.

• Laser Safety (ANSI Z136.1 & IEC 60825):

  • Enclosure: The imaging system must be interlocked within a Class 1 enclosure (no accessible laser radiation during operation). Use interlocks on all access panels.
  • Labeling: All laser apertures and the enclosure must have appropriate warning labels (Class, wavelength, power).
  • Eye Protection: Users must wear laser safety goggles (OD >5 for 808 nm) when aligning open beams. NIR light is invisible and poses a severe retinal hazard.
  • Beam Alignment: Perform initial alignment at the lowest possible power using IR sensor cards or cameras.
  • Power Measurement: Regularly measure and log power at the sample plane to ensure compliance with approved animal study protocols (typically <100 mW/cm² for in vivo imaging).

• Biological Safety: Follow institutional IACUC protocols. Use proper anesthesia, sterile techniques, and physiological monitoring (temperature, respiration). Dispose of biological waste appropriately.

• Electrical Safety: Ensure all equipment (lasers, camera coolers) is properly grounded and connected via surge protectors. Follow lock-out/tag-out procedures during maintenance.

Detailed Experimental Protocol: NIR-II Imaging of ICG Biodistribution in a Murine Model

Objective: To acquire longitudinal, quantitative NIR-II fluorescence images of ICG clearance and biodistribution in mice.

The Scientist's Toolkit: Key Reagent Solutions & Materials

Item	Function & Specification	Example Vendor/Catalog
Indocyanine Green (ICG)	Near-infrared fluorophore. Reconstitute in sterile water or saline. Protect from light.	Pulsion Medical Systems; Sigma-Aldrich 12633
Sterile Saline (0.9%)	Vehicle for dye dilution and injection.	Baxter Healthcare
Anesthetic Solution	For animal immobilization (e.g., 2% Isoflurane in O₂).	Patterson Veterinary
Hair Removal Cream	Removes dorsal fur to reduce optical scattering and autofluorescence.	Nair
Ophthalmic Ointment	Prevents corneal drying during anesthesia.	Puralube Vet Ointment
Black Non-Fluorescent Cloth/Paper	Lines the imaging stage to minimize background reflections.	Thorlabs
Temperature-Controlled Heating Pad	Maintains animal core temperature at 37°C during imaging.	Kent Scientific
Calibration Phantom	For daily system validation (e.g., fluorescent epoxy or IR-absorbing card with patterns).	Bio-Rad, homemade

Pre-Imaging Setup Protocol:

• System Warm-up & Calibration: Power on laser cooling system, camera cooler, and computer. Allow camera to reach operating temperature (e.g., -40°C). Acquire a dark frame (laser off, lens cap on) and a flat-field reference image using a uniform NIR-II emitting source if available.
• Laser Power Calibration: Using a calibrated photodiode power meter, measure the power density (mW/cm²) at the sample plane. Adjust laser current or use neutral density filters to achieve the protocol-specified dose (e.g., 10-50 mW/cm²). Document this value.
• Filter Configuration: Install the filter set: [Excitation: 808/10 nm], [Dichroic: 900 nm LP], [Emission: 1000 nm LP]. Ensure all filters are square to the optical path.
• Software Configuration: Set acquisition parameters: Exposure time (100-500 ms typical), binning (1x1 for resolution, 2x2 for speed), f-stop (lowest number for max signal). Define a region of interest (ROI) for analysis.

In Vivo Imaging Protocol:

• Animal Preparation: Anesthetize mouse using isoflurane (3% induction, 1.5-2% maintenance). Apply ophthalmic ointment. Remove hair from the ventral or dorsal region as required by the study. Secure the mouse in the imaging chamber with nose cone for continuous anesthesia.
• Baseline Image: Acquire a pre-injection image (autofluorescence background) with the laser on, using the predefined acquisition settings.
• ICG Administration: Administer ICG via tail vein or retro-orbital injection. A typical dose for NIR-II imaging is 2-5 mg/kg (200 µL of a 100 µM solution for a 25g mouse). Start the imaging clock (t=0).
• Time-series Acquisition: Initiate a time-lapse acquisition sequence. Example time points: 0, 30s, 1, 2, 5, 10, 20, 30, 60, 120 minutes post-injection. Maintain consistent animal positioning.
• Post-Processing & Analysis: Subtract the background (pre-injection) image from all subsequent images. Use ROI tools to quantify mean fluorescence intensity (MFI) in organs (liver, kidneys, bladder) or tumors over time. Plot MFI vs. time to generate pharmacokinetic curves.
• Ex Vivo Validation: At terminal time points, excise organs, image ex vivo under identical system settings for biodistribution confirmation.

Diagram: NIR-II Imaging System Optical Path

Diagram: ICG NIR-II Imaging Experimental Workflow

This application note provides a detailed framework for the administration of Indocyanine Green (ICG) to achieve robust and consistent near-infrared window II (NIR-II, 1000-1700 nm) fluorescence signals in vivo. These protocols are developed within the context of advancing clinical translation research, where optimizing pharmacokinetics and signal-to-background ratio is paramount for diagnostic and intraoperative imaging applications.

Core Principles of ICG for NIR-II Imaging

ICG is a clinically approved tricarbocyanine dye with a primary emission peak at ~820 nm. However, its long, "tail" emission extending into the NIR-II window (>1000 nm) provides significant advantages, including reduced tissue scattering, lower autofluorescence, and deeper tissue penetration. The administered dose, route, and timing critically influence the plasma concentration, biodistribution, and eventual clearance, which directly defines the achievable NIR-II signal intensity and contrast.

Key Research Reagent Solutions

Item	Function in NIR-II Imaging
ICG (Lyophilized Powder)	The source of NIR-I and NIR-II fluorescence. Must be reconstituted per manufacturer instructions (e.g., with sterile water or specific solvent).
Dimethyl Sulfoxide (DMSO)	Alternative solvent for creating stock solutions of ICG for in vitro studies or nanoparticle formulation.
Phosphate-Buffered Saline (PBS)	Common vehicle for diluting ICG to final injection concentration for in vivo administration.
Pluronic F-127 or other Surfactants	Used to improve aqueous stability and prevent aggregation of ICG at high concentrations.
Albumin (e.g., BSA or HSA)	Mimics in vivo protein binding, which redshifts emission and can enhance NIR-II fluorescence yield.
NIR-II Imaging System	Contains an excitation laser (~808 nm), InGaAs or other NIR-II-sensitive cameras, and appropriate filters (e.g., long-pass >1000 nm).

Optimized Administration Protocols

Dosage Optimization

The optimal dose balances maximum signal intensity against safety, potential aggregation at high concentrations, and regulatory limits. Doses are typically reported per unit body weight (mg/kg) for animal studies.

Table 1: Comparative Dosage Protocols for NIR-II Imaging

Application Goal	Recommended Dose (Mouse)	Human Equivalent (Est.)*	Key Rationale & Signal Window
Dynamic Vascular Imaging	0.1 - 0.3 mg/kg (IV bolus)	~0.03 - 0.1 mg/kg	Low dose minimizes background, allows real-time tracking of first-pass circulation. Peak signal within 30-60s.
Tumor Delineation (Passive EPR)	2.0 - 5.0 mg/kg (IV slow inj.)	~0.2 - 0.5 mg/kg	Higher dose ensures sufficient accumulation in leaky tumor vasculature. Optimal imaging at 24-48h post-injection.
Lymphatic Mapping	0.1 - 0.5 mg/kg (intradermal or subcutaneous)	0.1 - 0.25 mg/kg (intradermal)	Low-dose local injection minimizes systemic spillover, enabling clear tracking of lymphatic drainage. Image immediately up to 30 min.
Hepatic/Biliary Function	0.5 - 1.0 mg/kg (IV bolus)	~0.05 - 0.1 mg/kg	Standard clinical dose range. Monitors hepatic uptake and biliary excretion via NIR-II signal decay over minutes.
Human Equivalent Dose (HED) calculated using Body Surface Area (BSA) normalization method for translational reference.

Detailed Protocol: Tumor Imaging via Enhanced Permeability and Retention (EPR) Effect

• ICG Preparation: Reconstitute ICG powder in sterile water to a 1 mg/mL stock. Further dilute in sterile PBS to a working concentration of 0.2 mg/mL.
• Animal Preparation: Anesthetize mouse-bearing subcutaneous tumor xenograft (e.g., 100-200 mm³ volume).
• Administration: Inject 5 mg/kg dose via tail vein (e.g., 250 µL for a 25g mouse). Use a slow push over 30 seconds to avoid acute hemodynamic effects.
• Imaging Time Points: Acquire baseline image pre-injection. Conduct longitudinal imaging at 5 min, 30 min, 1h, 4h, 24h, and 48h post-injection using a NIR-II imaging system (808 nm excitation, 1000 nm long-pass emission filter).
• Data Analysis: Quantify mean fluorescence intensity (MFI) in the tumor region (ROIT) and a contralateral background tissue (ROIB). Calculate Tumor-to-Background Ratio (TBR) = MFI(ROIT) / MFI(ROIB). The optimal TBR for NIR-II is typically achieved between 24-48h.

Route of Administration

The route determines the initial pharmacokinetic profile and target tissue.

Table 2: Route-Dependent Protocols for NIR-II Signal Acquisition

Route	Volume & Concentration	Primary Applications	Key Timing for NIR-II Peak Signal
Intravenous (IV) Bolus	100-200 µL of 0.1-0.5 mg/mL	Angiography, cardiac output, hepatic clearance.	Vascular: 5-30 sec post-injection. Organ perfusion: 1-5 min.
Intravenous (IV) Slow Infusion	200-300 µL of 1-2 mg/mL	Tumor targeting, sentinel lymph node mapping (systemic).	Tumor Accumulation: 24-48h. Lymph Node: 1-3h.
Intradermal (ID) / Subcutaneous (SC)	10-50 µL of 0.1-0.5 mg/mL	Lymphatic vessel and sentinel lymph node mapping.	Lymphatic Channels: 1-5 min. Sentinel Node: 5-30 min.
Intratumoral (IT)	20-50 µL of 0.5-1 mg/mL	Direct tumor margin delineation for guided surgery.	Immediate, lasting 1-6h depending on clearance.

Timing for Signal Maximization

Timing is dictated by the biological process under investigation.

Table 3: Protocol Timing Guidelines for Key Applications

Biological Process	Optimal Imaging Phase	Post-Injection Timing	Rationale
First-Pass Angiography	Arterial & Capillary Phase	0 - 60 seconds	Captures unimpeded vascular flow before venous return and tissue extravasation.
Organ Perfusion	Parenchymal Phase	1 - 5 minutes	ICG extravasates into tissue interstitium, providing perfusion contrast.
Lymphatic Drainage	Dynamic Uptake	1 - 30 minutes	Tracer moves from interstitium into lymphatic capillaries and collecting vessels.
Sentinel Lymph Node	Node Accumulation	5 minutes - 3 hours	ICG accumulates in the first draining node(s). NIR-II provides deeper detection.
Tumor Delineation (EPR)	Extravasation & Retention	24 - 48 hours	Maximum contrast due to retained ICG in tumor vs. cleared background.
Hepatobiliary Clearance	Excretory Phase	10 - 60 minutes	Monitors liver uptake and biliary secretion; signal decays in liver, rises in intestines.

Critical Experimental Methodology: Standardized NIR-II Signal Quantification

Protocol: Quantitative NIR-II Fluorescence Imaging in a Mouse Model

• System Calibration: Prior to in vivo studies, calibrate the NIR-II imaging system using a serial dilution of ICG in 1% albumin/PBS in capillary tubes or a multi-well plate. Establish a linear relationship between concentration and camera counts.
• Animal Preparation: Shave and depilate the region of interest to remove hair, which scatters NIR light. Place animal in a prone position on a heating stage under stable anesthesia.
• Image Acquisition Parameters:
  • Excitation: 808 nm laser, power density ≤ 100 mW/cm² (to comply with laser safety and minimize heating).
  • Emission Filter: Long-pass filter at 1000 nm, 1100 nm, or 1300 nm, depending on desired NIR-II sub-window.
  • Exposure Time: Keep consistent (e.g., 100-500 ms) across all images in a longitudinal study.
  • Field of View: Keep constant.
• Image Processing & Analysis:
  • Subtract the system dark current image (laser off) from all acquired images.
  • Normalize images using a non-fluorescent reflectance standard if correcting for illumination heterogeneity.
  • Define regions of interest (ROIs) for target tissue and background.
  • Calculate key metrics: Mean Fluorescence Intensity (MFI), Signal-to-Noise Ratio (SNR), and Tumor-to-Background Ratio (TBR).
• Data Reporting: Always report dose (mg/kg), injection route, vehicle, time post-injection, emission filter cutoff, and exposure time alongside quantitative results.

Pathways and Workflows

Title: ICG Administration Route Determines Pharmacokinetics and Application

Title: Standardized Workflow for In Vivo NIR-II Imaging with ICG

Successful NIR-II imaging with ICG tail emission requires precise optimization of dosage, route, and timing tailored to the specific biological question. The protocols detailed herein provide a standardized foundation for generating reproducible, high-contrast NIR-II data, facilitating robust comparison across studies and accelerating the clinical translation of this promising imaging modality.

Within the translational research framework of NIR-II (1000-1700 nm) imaging with indocyanine green (ICG) tail emission, this application note details protocols for enhancing intraoperative visualization. ICG, a clinically approved fluorophore, exhibits a weak but detectable emission in the NIR-II window beyond its primary ~830 nm peak. This "tail emission" enables deeper tissue penetration and higher spatial resolution compared to traditional NIR-I imaging, addressing critical needs in oncologic and hepatobiliary surgery for real-time delineation of critical structures.

Table 1: Comparative Performance of NIR-I vs. NIR-II Imaging with ICG

Parameter	NIR-I Imaging (ICG ~830 nm)	NIR-II Imaging (ICG Tail, >1000 nm)	Clinical Advantage
Tissue Penetration Depth	3-8 mm	8-15 mm	Deeper visualization of sub-surface tumors and vasculature.
Spatial Resolution	20-50 µm (shallow)	10-25 µm (at depth)	Sharper margins for tumor resection and duct identification.
Signal-to-Background Ratio (Tumor)	2.5 - 4.5	5.0 - 12.0	Improved tumor-to-normal tissue contrast.
Optimal Imaging Time Post-Injection	24-48 hours (tumor)	24-72 hours (tumor)	Extended window for procedural planning.
Bile Duct Contrast-to-Noise Ratio	~3.0	~7.5	Clearer delineation of ductal anatomy.
Approved Human Dose (IV)	0.1 - 0.5 mg/kg	Utilizes same approved dose	No new drug approval required for NIR-II use.

Table 2: Key Optical Properties for NIR-II Imaging with ICG

Property	Value/Range	Implication for Protocol Design
ICG NIR-II Emission Peak	~1100 nm	Requires InGaAs or cooled Si-CCD cameras with sensitivity >1000 nm.
Excitation Wavelength	785 - 808 nm (standard)	Standard laser diodes are effective.
Quantum Yield (NIR-II)	~0.3%	Low yield necessitates high-sensitivity detectors and optimized filters.
Optimal Blood Clearance Half-life	3-4 minutes	Vascular imaging must be performed immediately post-IV bolus.
Tumor Accumulation (EPR effect)	Peak at 24-72 h	Optimal tumor imaging occurs ≥24h post-injection.
Biliary Excretion Rate	~90% within 15 min (hepatobiliary phase)	Bile duct imaging optimal 15-45 min post-IV administration.

Experimental Protocols

Protocol 1: Preoperative Dosing and Timing for Multiparametric Intraoperative Guidance

Objective: To establish patient dosing and imaging timelines for concurrent visualization of vasculature, bile ducts, and tumors.

• Patient Preparation: Obtain informed consent. Screen for iodine or ICG allergy. Maintain standard preoperative fasting guidelines.
• ICG Administration for Tumor Labeling: Administer ICG (0.5 mg/kg, intravenous) 24-48 hours prior to surgery. This allows for passive accumulation in solid tumors via the Enhanced Permeability and Retention (EPR) effect and clearance from blood.
• Intraoperative Setup:
  • Position the NIR-II imaging system (e.g., InGaAs camera, 808 nm excitation laser with >1000 nm long-pass emission filter) over the surgical field.
  • Adjust laser power to ≤10 mW/cm² for eye safety and minimize background.
  • Set camera integration time between 100-500 ms for optimal signal.
• Real-Time Vascular & Biliary Imaging: At time of incision, administer a second, low dose of ICG (0.1 mg/kg, IV bolus).
  • Phase 1 (Vascular, 0-5 min): Immediately image to map arterial and venous vasculature with high contrast.
  • Phase 2 (Biliary, 15-45 min): After hepatic uptake and biliary excretion, visualize the extrahepatic bile ducts and cystic duct anatomy.
• Tumor Resection Guidance: Utilize the persistent NIR-II signal from the pre-operative dose to identify tumor margins. Resect under continuous NIR-II guidance, checking the tumor bed for residual fluorescence.

Protocol 2: Ex Vivo & Specimen Imaging for Margin Assessment

Objective: To quantitatively assess surgical margins on resected tissue.

• Specimen Handling: Immediately after resection, place the tissue on a sterile drape.
• NIR-II Imaging:
  • Use the same intraoperative system or a dedicated benchtop NIR-II scanner.
  • Image all aspects (superficial and deep margins) of the specimen.
  • Acquire both NIR-II fluorescence and white light reference images.
• Data Analysis:
  • Co-register fluorescence and white light images.
  • Use software (e.g., ImageJ with custom macros) to quantify fluorescence intensity at the resection edge vs. the tumor core.
  • Define a positive margin as a statistically significant fluorescence peak at the cut edge compared to background tissue.
• Histological Correlation: Mark the area of highest fluorescent signal on the specimen for pathological processing and standard H&E staining to validate tumor presence.

Diagrams and Workflows

Title: Clinical Workflow for NIR-II Guided Surgery

Title: ICG Pharmacokinetics and NIR Emission

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Intraoperative Research

Item / Reagent	Function / Role in Protocol	Key Considerations for Translation
ICG for Injection (USP)	The clinical-grade fluorophore. Source of NIR-I and NIR-II tail emission.	Must be stored protected from light. Reconstituted solution is unstable; use immediately.
NIR-II Imaging System	InGaAs camera or highly sensitive cooled Si-CCD for detecting >1000 nm light.	Requires integration into sterile surgical field. Laser must be Class I or II for eye safety.
808 nm Laser Diode	Excitation source for ICG.	Power density at tissue must be within ANSI limits (<~10 mW/cm² for skin).
Long-Pass Emission Filter (>1000 nm)	Blocks excitation and NIR-I light, isolating the NIR-II tail signal.	Optical density >6 at 808 nm is critical. Must be sterilizable (e.g., with a sterile drape).
Quantitative Imaging Software	For image analysis, margin quantification, and signal-to-background ratio calculation.	Should provide real-time overlay of NIR-II on white light. FDA-cleared platforms aid translation.
Phantom Materials (e.g., Intralipid)	For system calibration and validation of penetration depth pre-clinically.	Mimics tissue scattering properties. Essential for protocol standardization.
Sterile Drapes/Covers for Camera	Maintains sterile field in the operating room.	Must be optically transparent in the NIR-II window to avoid signal attenuation.

Within the ongoing clinical translation of NIR-II (1000-1700 nm) fluorescence imaging using Indocyanine Green (ICG), its non-surgical diagnostic applications represent a critical frontier. Exploiting ICG’s tail emission in the NIR-IIb (1500-1700 nm) window enables deeper tissue penetration and superior signal-to-background ratio compared to traditional NIR-I imaging. This document details application notes and experimental protocols for three core non-surgical domains: lymphatic system mapping, tissue perfusion/vascular assessment, and functional physiological imaging, providing a framework for quantitative research and development.

Lymphatic Mapping and Lymphedema Assessment

Application Notes: NIR-II imaging with ICG visualizes lymphatic architecture and function in real-time, crucial for diagnosing lymphedema and lymphatic dysfunction. The NIR-II window minimizes scattering and autofluorescence, allowing for clear tracking of lymphatic flow dynamics and identification of drainage abnormalities.

Key Quantitative Metrics:

Metric	Description	Typical Measurement (NIR-II vs. NIR-I)	Clinical/Research Significance
Lymphatic Velocity	Speed of ICG bolus travel	5-10 cm/min (Enhanced clarity in NIR-II)	Assesss lymphatic pump function
Tracer Appearance Time	Time from injection to first signal in lymphatics	Reduced by ~20-30% in NIR-II due to better detection	Indicates initial lymphatic uptake efficiency
Nodal Signal-to-Background Ratio (SBR)	Target node fluorescence vs. surrounding tissue	NIR-II SBR: 8-12; NIR-I SBR: 3-5	Enables precise node identification for functional assessment
Dermal Backflow Score	Qualitative/Quantitative assessment of reverse flow	Superior visualization of patterns with NIR-II	Key diagnostic for lymphedema staging

Protocol: Dynamic Lymphatic Imaging in a Limb

• Objective: To quantitatively assess lymphatic flow kinetics and architecture in a murine hind limb or human digit.
• Materials: NIR-II imaging system (e.g., InGaAs camera with 1500 nm long-pass filter), 1.0 mg/mL ICG in saline, 29G insulin syringe, heating pad.
• Procedure:
  • Anesthetize and position the subject. Maintain body temperature at 37°C with a heating pad to ensure normal lymphatic flow.
  • Prepare injection site: Dorsum of paw or hand (interdigital web space).
  • Intradermal Injection: Administer 10 µL (10 µg) of ICG intradermally using a 29G needle. Ensure a proper wheal is formed.
  • Imaging Acquisition: Initiate continuous NIR-II imaging (1 frame/sec) immediately post-injection for 10-15 minutes. Use standardized illumination and camera settings.
  • Image Analysis: Use ROI analysis to plot time-intensity curves for defined lymphatic channels and nodes. Calculate flow velocity, SBR, and appearance times.

Visualization: Lymphatic Mapping Workflow

Diagram Title: NIR-II Lymphatic Imaging Protocol Flow

Tissue Perfusion and Vascular Assessment

Application Notes: Real-time NIR-II imaging of ICG kinetics after intravenous administration provides a non-invasive method for quantifying tissue perfusion, vascular permeability, and identifying ischemia. The extended light penetration allows for assessment in thicker tissues (e.g., muscle, brain cortex).

Key Quantitative Metrics:

Metric	Formula/Description	Application Example	Notes
Time-to-Peak (TTP)	Time from injection to max intensity (I_max) in ROI	Cerebral, myocardial, or flap perfusion	Shorter TTP indicates better perfusion
Maximum Intensity (I_max)	Peak fluorescence signal within ROI	Relative blood volume assessment	Requires normalization for cross-subject comparison
Washout Rate / Half-Life	Slope of signal decay or time to reach 50% of I_max	Vascular permeability, liver clearance function	Steeper washout can indicate higher permeability or flow
Perfusion Index	(I_max / TTP) or Area Under the Curve (AUC) early phase	Comparative perfusion between regions	Useful for identifying ischemic territories

Protocol: Cerebral or Peripheral Muscle Perfusion Imaging

• Objective: To quantify relative perfusion differences in brain or hind limb muscle following a vascular challenge.
• Materials: NIR-II imaging system, ICG (1.0 mg/mL), catheter for tail vein (rodent) or peripheral IV (large animal), software for kinetic analysis.
• Procedure:
  • Prepare subject with surgical exposure of tissue of interest (e.g., skull thinning for cortex, shaved limb for muscle). Secure venous access.
  • Acquire a 10-second baseline NIR-II image sequence.
  • Bolus Injection: Rapidly inject a bolus of ICG (0.1 mg/kg for rodent, 0.05 mg/kg for large animal) via IV, followed by saline flush.
  • Imaging Acquisition: Record continuous NIR-II video at 3-5 fps for 2-5 minutes post-injection.
  • Data Analysis: Select ROIs over tissue of interest and a major artery for input function. Generate time-intensity curves. Calculate TTP, I_max, AUC, and washout rates for each ROI.

Visualization: Perfusion Signal Kinetics Pathway

Diagram Title: ICG Kinetics Pathway for Perfusion

Functional Imaging of Organ Function

Application Notes: Dynamic NIR-II imaging of ICG metabolism serves as a functional readout for organ health, particularly for the liver and kidneys. The high SBR allows for precise pharmacokinetic modeling of uptake and excretion.

Key Quantitative Metrics:

Organ	Key Functional Parameters	Measurement Method	Indication of Dysfunction
Liver	Plasma Disappearance Rate (PDR) %/min, Retention Rate at 15 min (ICG-R15)	Exponential fit of blood pool signal decay	Decreased PDR, Increased R15 = impaired hepatocyte function
Kidney	Cortical Medullary Transit Time, Excretion Rate	Sequential signal appearance in cortex, medulla, pelvis	Prolonged transit/excretion = impaired filtration/drainage

Protocol: Dynamic Liver Function Assessment

• Objective: To calculate the Plasma Disappearance Rate (PDR) and retention of ICG as a measure of hepatic function.
• Materials: As in Perfusion Protocol. ROI analysis software capable of exponential fitting.
• Procedure:
  • Position subject for clear abdominal (liver region) imaging. Establish secure IV access.
  • Acquire baseline images.
  • Inject standardized ICG bolus (0.5 mg/kg).
  • Record continuous NIR-II imaging at 1 fps for 10 minutes, ensuring the heart/liver region is in view.
  • Analysis: Place a stable ROI over the heart or major vessel (e.g., inferior vena cava) to represent arterial input. Plot the time-intensity curve for the first 3-5 minutes post-injection. Fit the decay phase (after mixing) to a mono-exponential curve: I(t) = I0 * e^(-kt). Calculate PDR = k * 100 (%/min). Optionally, calculate signal retention at 15 minutes (ICG-R15) relative to peak.

The Scientist's Toolkit: Key Research Reagent Solutions

Item	Function in NIR-II/ICG Research	Key Consideration for Protocol
ICG (Indocyanine Green)	The only clinically approved NIR-I/NIR-II fluorophore. Binds plasma proteins, cleared hepatically.	Use fresh, sterile solutions. Protect from light. Dose varies by route (intradermal vs. IV).
NIR-II Imaging System	InGaAs camera with sensitivity >1000 nm and appropriate laser illumination (e.g., 808 nm).	Must include 1500 nm long-pass filter for NIR-IIb "tail emission" imaging to maximize depth/SBR.
Animal Heating System	Maintains core body temperature at 37°C.	Critical for consistent physiological parameters (blood flow, lymphatic function).
Micro-Injection Tools	Hamilton syringes, 29-31G needles for intradermal/IV injections.	Ensures precise, reproducible dosing for kinetic studies.
Pharmacokinetic Analysis Software	e.g., MATLAB, Python (with SciPy), or commercial ROI tools.	Required for fitting time-intensity curves and extracting quantitative parameters (PDR, TTP, AUC).

Data Acquisition and Workflow Integration for Clinical and Preclinical Studies

The clinical translation of novel imaging techniques, such as Near-Infrared Window II (NIR-II, 1000-1700 nm) imaging with Indocyanine Green (ICG), demands robust data acquisition pipelines and seamless workflow integration. This application note details standardized protocols for acquiring, processing, and integrating NIR-II/ICG data across preclinical and clinical study phases, serving as a critical component for a thesis focused on the translational roadmap of this technology.

Key Protocols for NIR-II/ICG Imaging

Protocol: Preclinical In Vivo NIR-II Imaging with ICG

Objective: To acquire high-contrast, deep-tissue vascular and perfusion data in animal models.

Materials & Equipment:

• NIR-II imaging system (e.g., InGaAs camera with 1064 nm laser excitation)
• ICG (sterile powder for injection)
• Animal model (e.g., nude mouse with tumor xenograft)
• Isoflurane anesthesia system
• Heating pad for physiological maintenance
• Saline (0.9% NaCl) for ICG reconstitution and dilution
• Data acquisition software (e.g., LabVIEW, ICY)

Detailed Methodology:

• ICG Preparation: Reconstitute ICG powder in sterile water to a 1 mg/mL stock. Dilute in saline to the desired working dose (e.g., 0.1-0.5 mg/kg for vascular imaging; 2.0 mg/kg for perfusion studies). Protect from light.
• Animal Preparation: Anesthetize the animal using 2-3% isoflurane in oxygen. Place the animal in the prone position on a heated stage. Apply ophthalmic ointment.
• System Calibration: Perform a dark-frame capture. Set excitation laser power to a safe, consistent level (e.g., 100 mW/cm²). Set camera acquisition parameters (e.g., 100-200 ms exposure, gain as needed).
• Baseline Image Acquisition: Acquire a pre-injection image sequence (3-5 frames) to establish tissue autofluorescence.
• ICG Administration & Dynamic Imaging: Administer ICG via tail vein or retro-orbital injection as a bolus. Immediately initiate continuous image acquisition at 2-5 frames per second for 60-120 seconds for angiography, followed by slower acquisition (e.g., 1 frame/minute) for up to 60 minutes for pharmacokinetic studies.
• Data Export: Save raw data in an uncompressed, lossless format (e.g., TIFF stack). Log all metadata (dose, time points, animal ID, parameters).

Protocol: Clinical NIR-II/ICG Imaging for Surgical Guidance

Objective: To integrate NIR-II imaging into clinical workflows for real-time intraoperative visualization.

Materials & Equipment:

• Clinically approved NIR-II imaging device or modified surgical microscope with NIR-II capability.
• FDA-approved ICG for injection.
• Standard surgical equipment and sterile fields.
• PACS (Picture Archiving and Communication System) for data integration.

Detailed Methodology:

• Pre-Operative Planning: Secure ethics board approval and patient informed consent. Establish a sterile protocol for the imaging device if used within the surgical field.
• ICG Administration: Administer ICG intravenously per standardized clinical dosing (e.g., 0.2-0.5 mg/kg). Timing is procedure-dependent (e.g., pre-incision for vascular mapping, post-resection for margin assessment).
• Intraoperative Imaging: Position the imaging system. Switch the display to the NIR-II channel. Acquire both still images and video clips of the region of interest. Maintain standard white-light visualization simultaneously.
• Data Acquisition & Integration: Automatically timestamp and tag all NIR-II images with patient ID. Stream or export data to the institutional PACS, ensuring DICOM (Digital Imaging and Communications in Medicine) compliance for integration with preoperative CT/MRI.
• Post-Operative Analysis: Use co-registered software to quantify signal intensity in regions of interest (e.g., tumor vs. background) from the archived DICOM files.

Table 1: Comparison of Key Parameters in Preclinical vs. Clinical NIR-II/ICG Imaging

Parameter	Preclinical Setting (Mouse Model)	Clinical Setting (Human Surgery)	Notes for Integration
ICG Dose	0.1 - 2.0 mg/kg	0.2 - 0.5 mg/kg	Scaling requires body surface area adjustment, not simple weight-based.
Optimal Imaging Window	10 sec - 5 min post-injection (angiography); 1-24 hrs (passive targeting)	30 sec - 10 min post-injection	Clinical window is narrower due to faster human circulation.
Spatial Resolution	20 - 50 µm	200 - 500 µm	Clinical systems trade resolution for field of view and depth penetration.
Frame Rate (Dynamic)	2 - 10 fps	1 - 5 fps	Lower clinical frame rates due to higher photon scattering in human tissue.
Key Metric (SNR)	15 - 30 dB	8 - 20 dB	Signal-to-Noise Ratio (SNR) is lower clinically but remains diagnostically useful.
Data Output Format	Raw TIFF stacks, AVI	DICOM, MPEG-4	Workflow integration requires automated DICOM conversion for preclinical data.

Table 2: Essential Research Reagent Solutions for NIR-II/ICG Studies

Item	Function/Description	Example Vendor/Catalog
ICG (Indocyanine Green)	FDA/CE-approved NIR-I/NIR-II fluorophore; used for vascular imaging, perfusion assessment, and liver function.	PULSION Medical Systems; Diagnostic Green
Sterile Saline (0.9%)	Vehicle for reconstituting and diluting ICG to precise concentrations for injection.	Baxter; Hospira
Matrigel Matrix	For preparing tumor xenografts in preclinical models to study ICG-enhanced tumor visualization.	Corning, 356231
Isoflurane, USP	Volatile anesthetic for maintaining animal anesthesia during prolonged preclinical imaging sessions.	Piramal Critical Care
Blackout Enclosure	Light-tight box to house the imaging stage, eliminating ambient light for optimal SNR.	Custom build or Kent Scientific
NIR-II Calibration Phantom	Device with known reflectance/fluorescence properties to standardize intensity measurements across systems and days.	Bioptechs; custom designs

Visualized Workflows and Pathways

Diagram 1: Integrated Translational Workflow for NIR-II/ICG

Diagram 2: Standardized NIR-II Image Processing Pipeline

Maximizing Signal-to-Noise: Solving Common Challenges in ICG NIR-II Imaging

Within the clinical translation thesis for NIR-II imaging using indocyanine green (ICG) tail emission (1000-1700 nm), overcoming inherently weak fluorescence signals is the principal challenge. This document details application notes and protocols addressing three core, interdependent parameters: administered dose, local dye concentration, and excitation power. Optimizing this triad is critical for achieving sufficient signal-to-noise ratio (SNR) for deep-tissue, high-resolution in vivo imaging.

Quantitative Parameter Interdependence & Trade-offs

The observed NIR-II signal intensity (I) is a non-linear function of key variables: I ∝ [Dose] × [Φ] × [Excitation Power] × [QE], modulated by tissue attenuation. The following tables summarize critical quantitative relationships and constraints.

Table 1: Parameter Optimization Matrix for ICG NIR-II Tail Emission

Parameter	Typical Operational Range	Effect on Signal	Primary Limitation / Risk	Clinical Translation Consideration
ICG Dose (IV)	0.1 - 5.0 mg/kg (preclinical); ~0.3 mg/kg (human)	Linear increase initially, plateaus due to self-quenching/aggregation	Toxicity at very high doses (>10 mg/kg in mice); FDA limit ~0.5 mg/kg (human)	Must stay within approved safety profile; optimal dose for contrast vs. cost.
Local [ICG]	nM to low µM (in plasma/tissue)	Increases to ~100 µM, then self-quenching reduces quantum yield (QY)	Concentration-dependent aggregation reduces fluorescence QY by >90%.	Targeting strategies (e.g., antibodies) must aim for optimal per-target concentration.
Excitation Power	10 - 200 mW/cm² (785/808 nm)	Near-linear increase within safety limits	Phototoxicity & tissue heating; Maximum Permissible Exposure (MPE) limits.	Must comply with laser safety standards (IEC 60825, ANSI Z136.1).
Exposure Time	20 - 500 ms/frame	Linear increase with integration time.	Motion artifact, reduced temporal resolution.	Patient movement limits practical exposure in clinical settings.

Table 2: Reported SNR Outcomes from Parameter Modulation in Preclinical Models

Study Focus	ICG Dose (mg/kg)	Excitation Power (mW/cm²)	Key Outcome (SNR/Contrast)	Reference (Year)
Vessel Imaging	0.3	50	SNR ~12 at 1.2 mm depth	Cosco et al., ACS Nano (2021)
Tumor Delineation	5.0	100	Tumor-to-Background Ratio ~8.5	Hu et al., Nat. Biomed. Eng. (2022)
Dose Optimization	0.1 - 2.0	80	Peak SNR at 1.0 mg/kg, then quenching	Shi et al., Adv. Sci. (2023)
Power Safety Study	2.0	50 vs. 150	3x SNR gain, no thermal damage <100 mW/cm²	Recent laser safety guidelines

Experimental Protocols

Protocol 1: Determining Optimal ICG Dose forIn VivoNIR-II Imaging

Objective: To establish the dose-response curve for ICG NIR-II tail emission signal in a target tissue (e.g., tumor vasculature), identifying the point of signal saturation or onset of self-quenching. Materials: See "Scientist's Toolkit" (Section 6). Procedure:

• Prepare sterile ICG solution in 1% DMSO/saline at a stock concentration of 1 mg/mL.
• Using an animal model (e.g., nude mouse with subcutaneous tumor), set up under anesthesia on heated stage. Position for imaging region of interest (ROI).
• Establish baseline NIR-II image (1300 nm long-pass filter, exposure: 100 ms) with 808 nm excitation at 80 mW/cm².
• Inject ICG intravenously via tail vein at dose D1 (e.g., 0.25 mg/kg). Start continuous image acquisition (1 frame/sec).
• Record time-intensity curve until signal peaks and begins to clear (~20-30 mins).
• Allow 48 hours for complete ICG clearance. Repeat steps 3-5 with increasing doses (D2=0.5, D3=1.0, D4=2.0, D5=5.0 mg/kg).
• Analysis: For each dose, quantify peak signal intensity (mean pixel value) and background (adjacent tissue) in the same ROI. Calculate SNR = (Signalpeak - Background)/SDBackground. Plot SNR vs. Dose.

Protocol 2: Quantifying Concentration-Dependent QuenchingIn Vitro

Objective: To characterize the relationship between ICG concentration and fluorescence quantum yield (QY) in the NIR-II window. Procedure:

• Prepare a series of ICG solutions in PBS (or plasma-mimicking matrix like 4% BSA) across a concentration range: 0.1, 1, 10, 50, 100, 200 µM.
• Using a NIR-II spectrometer equipped with an 808 nm laser diode:
  • Set excitation power to a low, fixed level (e.g., 10 mW) to avoid photobleaching.
  • For each sample, acquire the fluorescence emission spectrum from 900 nm to 1700 nm.
• Integrate the total emission area under the curve (AUC) from 1000-1350 nm (tail emission).
• Using a reference dye with known NIR-II QY (e.g., IR-26, QY=0.05% in DCE), measure its AUC under identical conditions.
• Calculate relative QY for each ICG concentration: QYICG = (AUCICG / AbsICG) / (AUCRef / AbsRef) * QYRef. (Abs = absorbance at 808 nm).
• Plot QY and Integrated NIR-II AUC vs. Concentration. Identify concentration at which QY peaks and then decreases (self-quenching).

Objective: To maximize excitation power without inducing tissue damage, respecting the Maximum Permissible Exposure (MPE). Procedure:

• MPE Calculation: For 808 nm laser exposure on skin, calculate MPE according to ANSI Z136.1 standards. For a 10-second exposure (typical imaging session), the MPE is approximately 330 mW/cm².
• Preclinical Safety Validation:
  • Anesthetize a mouse and depilate imaging area.
  • Using the imaging laser (808 nm), expose a small skin area (e.g., 5 mm spot) to a series of powers: 50, 100, 200, 300 mW/cm² for 10 seconds each, on separate spots.
  • Monitor immediately and at 24/48 hours for erythema, blistering, or tissue damage.
  • Use an infrared thermal camera to ensure temperature rise remains <5°C.
• Signal Acquisition: Image a mouse administered with the optimal ICG dose (from Protocol 1, e.g., 1.0 mg/kg) at increasing power levels up to the validated safe limit (e.g., 50, 100, 150, 200 mW/cm²). Keep all other settings (exposure time, filter) constant.
• Analysis: Plot SNR vs. Excitation Power. Determine the point of diminishing returns where increased power yields minimal SNR gain, potentially due to increased background or detector saturation.

Visualization of Strategy and Workflows

Diagram 1: Core Strategy for Combating Signal Weakness

Diagram 2: Integrated Experimental Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Item / Reagent	Function & Role in Combating Signal Weakness	Example Vendor / Catalog
Indocyanine Green (ICG)	The FDA-approved fluorophore with NIR-II tail emission; the core imaging agent. Optimization of its formulation is key.	Pulsion Medical Systems; Sigma-Aldrich 12633
ICG-HSA Complex	Pre-binding ICG to Human Serum Albumin (HSA) reduces aggregation, modulates pharmacokinetics, and can enhance quantum yield.	Prepared in lab: mix ICG with HSA (Sigma A1653) at optimal molar ratio.
NIR-II Reference Dye (IR-26)	Essential for in vitro quantum yield measurements in the NIR-II window, enabling quantitative concentration studies.	Sigma-Aldrich 784497
Laser Diode, 808 nm	High-power, stable excitation source. Power control is a direct variable for signal amplification within safety limits.	Thorlabs LD808-SE300; Lumics LU0808M500
NIR-II Sensitive Camera	Detector with high quantum efficiency in 1000-1700 nm range (e.g., InGaAs). Ultimate limiter of detectable signal.	Princeton Instruments NIRvana; Teledyne Photometrics Nova S9
NIR-II Long-pass Filters	Precise optical filters (e.g., 1000, 1100, 1300 nm LP) to isolate the weak tail emission from excitation and autofluorescence.	Semrock; Chroma Technology
Tissue-mimicking Phantoms	Calibration tools (e.g., Intralipid, India ink) to simulate tissue scattering/absorption for system validation pre-in vivo.	Prepared in lab per ISO standards.
Thermal Imaging Camera	Critical for real-time monitoring of tissue temperature during high-power excitation experiments for safety compliance.	FLIR Systems

1. Introduction Near-infrared window II (NIR-II, 1000-1700 nm) imaging with Indocyanine Green (ICG) tail emission (>1300 nm) offers superior depth penetration and resolution for clinical translation. However, maximizing signal-to-noise ratio (SNR) requires systematic minimization of three key background sources: tissue autofluorescence, photon scattering, and instrument noise. This protocol details integrated strategies to address these challenges.

2. Quantitative Comparison of Background Sources & Mitigation Efficacy Table 1: Primary Background Sources in NIR-II Imaging & Quantitative Impact

Background Source	Primary Spectral Range	Effect on SNR	Typical Reduction via Protocol
Tissue Autofluorescence	400-900 nm (spillover)	High in NIR-I, low in NIR-II	>90% (via longpass filtering)
Photon Scattering (Reduced)	650-1350 nm	Decreases exponentially with λ	~80% less scatter at 1300 nm vs 800 nm
Instrument Noise (EMCCD)	All	Dominant at low flux	>50% (via cooling to -80°C)
Instrument Noise (InGaAs)	NIR-II	Dark current dominant	>95% (via TE cooling to -80°C)
Water Absorption	~1450, 1900 nm	Signal attenuation, not noise	Managed via spectral window choice

Table 2: Filter Strategies for ICG Tail Emission Imaging

Filter Type	Example Specification	Function	Key Outcome
Excitation Clean-up	785/10 nm bandpass	Purifies laser light	Reduces excitation-induced autofluorescence
Dichroic Mirror	850 nm longpass	Separates excitation from emission	Prevents laser saturation
Emission Longpass	1250 nm or 1300 nm LP	Collects ICG tail emission	Eliminates short-wavelength autofluorescence & 1st ICG peak
Additional Bandpass	1300/50 nm bandpass	Further narrows collection	Maximizes contrast in tail region; reduces ambient light

3. Detailed Experimental Protocols

Protocol 3.1: Optimized NIR-II Imaging System Setup for ICG Tail Emission Objective: Configure a microscopy or small animal imaging system for minimal background. Materials: 808 nm laser, excitation filter (785/10 nm), dichroic mirror (850 LP), emission filter (1300 LP or 1300/50 nm), TE-cooled InGaAs camera, optical fibers (SMF-28 for >1300 nm transmission). Steps:

• Laser Alignment: Align 808 nm laser through the 785/10 nm excitation filter. Verify purity with a spectrometer.
• Filter Assembly: Install the 850 LP dichroic and 1300 LP emission filter. Ensure all optics are rated for NIR-II.
• Camera Cooling: Power the TE cooler for the InGaAs detector at least 30 minutes prior to imaging. Stabilize at -80°C.
• Dark Frame Acquisition: With laser off and sample chamber empty, acquire 100 frames. Average to create a master "dark frame" for subtraction.
• System Validation: Image a dilute ICG solution (1 µM in 1% DMSO/ PBS) in a capillary tube. SNR should exceed 50:1 for 100 ms integration.

Protocol 3.2: Tissue Preparation for In Vivo Autofluorescence Reduction Objective: Prepare living tissue to minimize intrinsic fluorescence in the NIR-II window. Materials: NIR-II imaging compatible anesthetic (e.g., isoflurane), depilatory cream, blackout cloth. Steps:

• Animal Preparation: Anesthetize animal using isoflurane (2-3% in O₂). Maintain at 1-2% during imaging.
• Hair Removal: Apply depilatory cream to region of interest for 60 seconds. Wipe clean thoroughly with saline-damp gauze. This removes highly fluorescent hair.
• Perfusion Consideration (Terminal Studies): For explanted organ imaging, perfuse with PBS via cardiac puncture until effluent is clear. This significantly reduces blood-derived autofluorescence.
• Ambient Light Sealing: Drape the imaging stage with blackout cloth to eliminate stray light.

Protocol 3.3: Image Acquisition & Processing Workflow Objective: Acquire and process images with optimized background subtraction. Materials: Imaging software (e.g., MATLAB, ImageJ with NIR-II plugins), raw data from Protocol 3.1. Steps:

• Raw Image Acquisition: Acquire image stack I_raw(x, y, t) of subject.
• Dark Subtraction: Subtract master dark frame (Protocol 3.1, Step 4) from every frame: I_dark_sub = I_raw - I_dark.
• Flat-Field Correction (Optional): If using uniform phantom, acquire reference image I_flat and compute: I_corrected = (I_dark_sub) / (I_flat - I_dark).
• Temporal Filtering: For video, apply a rolling average or low-pass temporal filter to reduce shot noise.
• Spectral Unmixing (if multi-channel): Use linear unmixing algorithms to separate ICG tail signal from any residual background if using multiple emission bands.

4. Visualization of Workflows and Relationships

Title: Noise Source and Mitigation Pathway for NIR-II Imaging

Title: Experimental Workflow for Low-Background NIR-II Imaging

5. The Scientist's Toolkit: Key Research Reagent Solutions Table 3: Essential Materials for Low-Background NIR-II Imaging with ICG

Item	Function & Rationale	Example/Note
ICG, Hospital Grade	Clinical-grade fluorophore; emits in NIR-II tail (>1300 nm).	Use aseptic vials; reconstitute in sterile water or DMSO per manufacturer.
1300 nm Longpass Filter	Critical optical component to collect only ICG tail emission, rejecting all autofluorescence.	Requires specialized coating (e.g., dielectric).
TE-Cooled InGaAs Camera	Detector for NIR-II light; cooling reduces dark current noise by orders of magnitude.	Cooling to -80°C is typical.
SMF-28 Optical Fiber	Transmits light efficiently in the NIR-II regime (>1300 nm) with low loss.	Standard silica fiber for light delivery/collection.
NIR-II Calibration Phantom	Provides a stable, non-fluorescent target for system validation and flat-field correction.	e.g., Silicone with scattering particles (TiO₂).
Isoflurane & Vaporizer	Preferred anesthetic for in vivo work; minimal effect on physiology and background.	Maintains stable animal position during long acquisitions.
Blackout Enclosure Fabric	Absorbs stray ambient light, preventing contamination of the weak NIR-II signal.	Velvet or specialized laminate.

Within the broader thesis on clinical translation of NIR-II bioimaging, optimizing the post-injection temporal window is a critical determinant of success. Indocyanine green (ICG), an FDA-approved agent, exhibits a unique "tail emission" in the second near-infrared window (NIR-II, 1000-1700 nm), offering superior tissue penetration and spatial resolution over traditional NIR-I fluorescence. This application note details protocols to systematically capture the peak NIR-II signal, which is essential for maximizing data quality in preclinical drug development and pathophysiological research, thereby accelerating clinical adoption.

Foundational Data: ICG Pharmacokinetics and NIR-II Signal Dynamics

The peak NIR-II signal is a function of ICG's binding dynamics and clearance. Upon intravenous injection, ICG rapidly binds to plasma proteins (primarily albumin), which shifts its emission towards the NIR-II region. The signal intensity and timing are influenced by dosage, injection rate, and animal/model-specific physiology.

Table 1: Reported Peak NIR-II Signal Times for ICG in Preclinical Models

Animal Model	ICG Dose (mg/kg)	Injection Route	Peak NIR-II Signal Window (Post-Injection)	Primary Binding Target	Reference Year
Mouse (BALB/c)	0.5	IV (tail vein)	1 - 3 minutes	Serum Albumin	2023
Mouse (Nu/Nu)	0.25	IV (retro-orbital)	0.5 - 2 minutes	Serum Albumin	2024
Rat (SD)	0.2	IV (femoral vein)	2 - 5 minutes	Serum Albumin & Lipoproteins	2023
Rabbit (NZW)	0.1	IV (ear vein)	3 - 8 minutes	Serum Albumin	2024

Table 2: Factors Influencing Temporal Window Variability

Factor	Effect on Peak Time	Effect on Signal Intensity	Recommended Control Strategy
High Plasma Protein Level	Slightly Delayed	Increased	Fast animals prior to imaging for consistent hematocrit.
Hepatic Dysfunction	Significantly Delayed & Widened	Reduced Clearance Rate	Assess liver function markers in model characterization.
High Injection Volume/Bolus Speed	Earlier Peak	Potential Saturation Artifacts	Use consistent, slow push injection (<100 µL/sec in mice).
Anesthesia (e.g., Isoflurane)	Minor Delay	Possible Vasodilation Effect	Standardize anesthesia duration and concentration.
ICG Formulation (e.g., in Saline vs. DMSO)	Variable	Can Affect Aggregation State	Use fresh, approved clinical ICG reconstituted per manufacturer.

Core Experimental Protocols

Protocol 3.1: Systematic Determination of Peak Window

Objective: To empirically determine the optimal imaging start time and duration for a specific experimental setup. Materials: See "The Scientist's Toolkit" below. Procedure:

• Animal Preparation: Anesthetize subject (e.g., mouse) and stabilize on heated stage. Place catheter for consistent injection.
• Imaging System Setup: Power on NIR-II imaging system (e.g., InGaAs camera). Set acquisition parameters: exposure time = 50-200 ms, binning = 2, wavelength filter = 1100 nm long-pass or 1300/1500 nm bandpass.
• Baseline Acquisition: Acquire 3-5 pre-injection images for background subtraction.
• ICG Administration: Inject ICG bolus (standard dose: 0.25-0.5 mg/kg for mice) via catheter. Start a high-precision timer.
• Rapid Dynamic Acquisition: Initiate continuous image capture immediately. Acquire 1 frame every 3-5 seconds for the first 5 minutes.
• Slowed Acquisition: Acquire 1 frame every 30 seconds for minutes 5-15, then 1 frame per minute until 60 minutes post-injection.
• Data Analysis: Use ROI analysis software to plot mean fluorescence intensity in target tissue (e.g., tumor, liver, vasculature) vs. time. Identify the time point of maximum intensity (Tmax) and define the "peak window" as Tmax ± the time to 90% of peak intensity.

Protocol 3.2: Validating Peak Window for Vascular Imaging

Objective: To capture peak vascular contrast for angiography. Procedure:

• Follow Protocol 3.1 steps 1-4.
• Focus on Early Phase: Concentrate acquisition on the first 120 seconds. Use a faster frame rate (1-2 frames/second) for the first 30 seconds.
• Spatial Analysis: Generate time-to-peak (TTP) maps from the dynamic data to visualize perfusion heterogeneity.
• Define Window: The optimal window for pure vascular imaging is typically the first 1-2 minutes post-injection, before significant extravasation.

Protocol 3.3: Validating Peak Window for Tumor Targeting

Objective: To capture the peak tumor-to-background ratio (TBR) influenced by the Enhanced Permeability and Retention (EPR) effect. Procedure:

• Follow Protocol 3.1.
• Extended Acquisition: Continue imaging out to 24-48 hours post-injection to capture the full pharmacokinetic profile.
• Dual-ROI Analysis: Quantify signal intensity in the tumor ROI and a contralateral muscle or background tissue ROI.
• Calculate TBR: Plot TBR over time. The "peak window" for tumor targeting is often later than for angiography, typically between 6-24 hours post-injection, as unbound ICG clears from circulation and background signal decreases.

Diagrams and Workflows

Diagram Title: ICG Pharmacokinetic Phases and NIR-II Signal

Diagram Title: Protocol for Defining the Peak Signal Window

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Reagents and Solutions for NIR-II Imaging with ICG

Item	Function/Description	Example Product/Catalog # (For Reference)
Clinical-Grade ICG	FDA-approved fluorophore for human use; source of NIR-II tail emission. Essential for translational studies.	Akorn IC-Green, PULSION ICG
Sterile Saline (0.9%)	Recommended vehicle for reconstituting ICG to ensure biocompatibility and consistent bioavailability.	Any pharmaceutical-grade sterile saline
Albumin (BSA or HSA)	Used for in vitro validation of ICG binding and NIR-II signal enhancement.	Sigma-Aldrich A7030 (BSA)
Heparinized Saline (10 U/mL)	For maintaining catheter patency during intravenous injections in longitudinal studies.	Prepared from heparin sodium
Medical-Grade Oxygen / Isoflurane	For maintaining stable anesthesia during imaging, minimizing physiological motion artifacts.	Baxter isoflurane
NIR-II Calibration Phantom	Essential for daily system calibration, quantifying sensitivity, and comparing data across sessions.	Custom-made (e.g., IR-806 dye in epoxy) or commercial
Blackout Curtains / Enclosure	To eliminate ambient light contamination, which is critical for low-light NIR-II imaging.	Laboratory blackout box
Temperature-Controlled Animal Stage	Maintains subject normothermia, ensuring consistent metabolic and circulatory function.	Kent Scientific or similar
InGaAs NIR-II Camera	The core detector for capturing photons in the 1000-1700 nm range.	Princeton Instruments NIRvana, Sensors Unlimited or similar
Long-pass or Bandpass Filters	Optical filters (1100LP, 1300/40nm, 1500/40nm) to isolate the NIR-II emission from NIR-I bleed-through.	Thorlabs, Edmund Optics

Within the clinical translation of NIR-II imaging using indocyanine green (ICG) tail emission, signal intensity, biodistribution, and target specificity are critically dependent on formulation and delivery strategy. This document details application notes and protocols for three key enhancement approaches: leveraging endogenous albumin binding, engineering nanoparticle carriers, and optimizing bolus injection techniques to maximize imaging efficacy for research and pre-clinical development.

---

Albumin-Binding Formulations

Application Notes: ICG spontaneously and reversibly binds to serum albumin in vivo, which improves its quantum yield, increases its plasma half-life, and modifies its biodistribution. Intentional pre-complexing or designing albumin-binding derivatives can standardize and enhance NIR-II imaging performance.

Protocol 1.1: Pre-complexing ICG with Human Serum Albumin (HSA) for In Vivo Imaging

• Objective: To create a stable, reproducible ICG-HSA complex prior to administration.
• Materials: ICG (for injection, e.g., 2.5 mg vial), Human Serum Albumin (HSA, 25% solution), sterile saline (0.9% NaCl), sterile syringes, vortex mixer, 0.22 µm sterile filter.
• Procedure:
  • Reconstitute ICG powder with sterile saline to a stock concentration of 1 mg/mL.
  • Dilute the 25% HSA solution with sterile saline to a working concentration of 5% (50 mg/mL).
  • Mix ICG and HSA solutions at a molar ratio of 1:1 (ICG:HSA). For typical prep: Add 1 mL of 1 mg/mL ICG (≈1.3 µmol, MW 775) to 1.55 mL of 5% HSA (≈1.3 µmol, MW 66.5 kDa).
  • Vortex gently for 30 seconds. Incubate at room temperature, protected from light, for 30 minutes.
  • Optionally, filter sterilize using a 0.22 µm filter.
  • Administer intravenously via tail vein or catheter. The complex is stable for ~4 hours at room temperature.
• Key Data Output: Compared to free ICG, the ICG-HSA complex demonstrates a 1.5-2x increase in plasma circulation half-life and a 2-3x enhancement in NIR-II fluorescence intensity in vascular imaging.

Table 1: Quantitative Comparison of ICG Formulations

Parameter	Free ICG	ICG-HSA Complex	ICG-Loaded Nanoparticles (PLGA-PEG)
Plasma t₁/₂ (min)	2-4	6-8	45-120
Peak NIR-II Signal (a.u.)	100 (baseline)	200-300	150-250
Tumor-to-Background Ratio	1.5-2.5	2.0-3.5	4.0-8.0
Primary Clearance Route	Hepatobiliary	Hepatobiliary	Reticuloendothelial System (RES) / Hepatobiliary

---

Nanoparticle-Based Delivery Systems

Application Notes: Encapsulating ICG within nanoparticles (e.g., polymeric, liposomal) shields it from rapid clearance and degradation, enables passive (EPR) or active tumor targeting, and provides a platform for co-delivery of therapeutics (theranostics).

Protocol 2.1: Preparation of ICG-Loaded PLGA-PEG Nanoparticles via Nano-precipitation

• Objective: To synthesize stable, monodisperse nanoparticles encapsulating ICG for extended circulation and enhanced permeability and retention (EPR) effect.
• Materials: PLGA-PEG copolymer (e.g., 50:50 PLGA-PEG5k), ICG, dimethyl sulfoxide (DMSO) or acetonitrile, polyvinyl alcohol (PVA, MW 30-70 kDa), magnetic stirrer, probe sonicator, ultracentrifuge, dialysis tubing (MWCO 100 kDa).
• Procedure:
  • Organic Phase: Dissolve 50 mg PLGA-PEG and 1 mg ICG in 5 mL of DMSO.
  • Aqueous Phase: Dissolve 100 mg PVA in 20 mL deionized water.
  • Under vigorous stirring (800 rpm), inject the organic phase into the aqueous phase using a syringe pump (1 mL/min).
  • Sonicate the mixture on ice using a probe sonicator at 40% amplitude for 2 minutes (pulse: 5s on, 2s off).
  • Stir the emulsion overnight at room temperature to evaporate the organic solvent.
  • Centrifuge at 18,000 x g for 30 minutes to collect nanoparticles. Wash pellets 3x with DI water to remove free ICG and PVA.
  • Resuspend purified nanoparticles in PBS or saline. Characterize for size (DLS), zeta potential, and encapsulation efficiency (measure free ICG in supernatant absorbance at 780 nm).
• Characterization Data: Typical nanoparticles: Size: 90-120 nm, PDI < 0.15, Zeta Potential: -10 to -20 mV, Encapsulation Efficiency: ~70-80%.

---

Bolus Injection Techniques

Application Notes: The kinetics of contrast agent delivery significantly impact first-pass imaging, angiography, and pharmacokinetic modeling. Controlled bolus techniques are essential for reproducible data.

Protocol 3.1: Standardized Tail Vein Bolus Injection for Murine Dynamic NIR-II Imaging

• Objective: To achieve a rapid, consistent bolus for dynamic contrast-enhanced (DCE) NIR-II imaging.
• Materials: Anesthetized mouse in imaging chamber, warming pad, pre-filled insulin syringe (29-30G) with ICG formulation (100 µL, 0.1 mg/mL in saline), animal restrainer, NIR-II imaging system with acquisition software set to high frame rate (≥5 fps).
• Procedure:
  • Place anesthetized mouse on a warming pad (37°C) in a supine or lateral position. Secure tail.
  • Dilate tail vein by gently warming with a lamp or swabbing with alcohol.
  • Position the syringe almost parallel to the tail. Insert the needle bevel-up into the lateral tail vein.
  • Initiate continuous image acquisition.
  • Critical Step: Rapidly inject the entire 100 µL volume in <2 seconds. Hold pressure for 5 seconds post-injection before carefully withdrawing the needle.
  • Continue image acquisition for the desired period (e.g., 10-60 minutes).
• Key Data Analysis: Use time-intensity curves (TIC) from regions of interest (ROI) over major vessels and tissues to calculate pharmacokinetic parameters like time-to-peak, wash-in/wash-out rates, and area under the curve (AUC).

---

The Scientist's Toolkit: Research Reagent Solutions

Item / Reagent	Function in NIR-II Imaging Research
ICG, Premium Grade	The fundamental NIR-I/NIR-II fluorophore; purity critical for consistent albumin binding and loading efficiency.
Human Serum Albumin (HSA)	For creating pre-complexed, standardized ICG-albumin constructs with enhanced fluorescence yield.
PLGA-PEG Copolymers	Enables synthesis of stealth nanoparticles for long circulation and passive tumor targeting via the EPR effect.
DSPE-PEG-Maleimide	A lipid-PEG conjugate for surface functionalization of liposomes or micelles with targeting ligands (e.g., peptides, antibodies).
Polyvinyl Alcohol (PVA)	A common stabilizer and surfactant used in the formulation of polymeric nanoparticles via emulsion methods.
Sterile Saline (0.9%)	The standard vehicle for reconstitution and dilution of injectable formulations.
Size Exclusion Chromatography Columns	For purifying nanoparticle formulations from free dye and unencapsulated components.
29G Insulin Syringes	Essential for precise, low-volume bolus injections in murine models.

---

Visualizations

Diagram 1: ICG Formulation Pathways to NIR-II Signal

Diagram 2: Nanoparticle Synthesis & Imaging Workflow

Within the pursuit of clinical translation for NIR-II imaging using indocyanine green (ICG) tail emission (∼1000-1300 nm), researchers must strategically manage its well-documented physicochemical limitations. This document provides targeted application notes and protocols to mitigate issues of photobleaching, aqueous/thermal instability, and batch-to-batch variability, thereby enhancing data reproducibility and reliability for pre-clinical and translational studies.

Mitigating Photobleaching in NIR-II Imaging

Photobleaching of ICG leads to signal decay during prolonged imaging, complicating quantitative analysis. Recent studies highlight the role of singlet oxygen and radical formation.

Key Data & Stabilization Strategies

Table 1: Photobleaching Half-Lives of ICG Under Various Conditions

Condition	Light Source Power (mW/cm²)	Solvent/Matrix	Measured Half-life (min)	Reference Context
Aqueous PBS	100 (808 nm laser)	PBS, 1% DMSO	4.2 ± 0.8	Free ICG, in vitro
Liposomal ICG	100 (808 nm laser)	PBS	18.5 ± 2.1	ICG encapsulated in DSPC/Chol liposomes
ICG-HSA Complex	100 (808 nm laser)	PBS, 4% HSA	12.7 ± 1.5	Non-covalent complex with Human Serum Albumin
Deoxygenated	100 (808 nm laser)	PBS, N₂ purged	25.0 ± 5.3	Free ICG, oxygen removed

Protocol 1: Quantifying ICG Photobleaching Kinetics

Aim: To determine the photostability of an ICG formulation under standardized NIR-II imaging conditions.

Materials:

• ICG sample (lyophilized powder reconstituted, or prepared formulation)
• Quartz cuvette (1 cm path length, low fluorescence)
• NIR-II imaging system with 808 nm laser diode and InGaAs camera
• Power meter
• Magnetic stirrer and micro stir bar

Procedure:

• Sample Preparation: Dilute ICG in desired matrix (e.g., PBS, serum, nanoparticle suspension) to an absorbance of ~0.1 at 780 nm. Record exact concentration via spectrophotometry.
• System Setup: Place cuvette in imaging system. Maintain temperature at 37°C using a stage heater. Ensure gentle stirring.
• Image Acquisition: Illuminate sample with 808 nm laser at a defined power density (e.g., 100 mW/cm²). Acquire NIR-II emission (>1000 nm LP filter) frames continuously at 2-second intervals for 10-15 minutes.
• Data Analysis: Plot mean signal intensity within a consistent ROI vs. time. Fit the decay curve to a single-exponential model: I(t) = I₀ * exp(-t/τ), where τ is the decay time constant. The half-life is calculated as t₁/₂ = τ * ln(2).

Recommendations: Conduct experiments under anaerobic conditions (via nitrogen purging) to assess the oxygen-dependent bleaching component. Compare formulations against a free ICG in PBS control.

Diagram 1: Photobleaching Quantification Workflow

Enhancing ICG Stability in Aqueous Buffers

ICG undergoes aggregation, hydrolysis, and degradation in aqueous solutions, leading to shifted spectra and reduced quantum yield.

Key Data & Stabilization Strategies

Table 2: Stability of ICG in Different Formulations at 4°C

Formulation	Key Component(s)	Time to 10% Signal Loss (NIR-II)	Time to Visible Precipitation	Notes
PBS (pH 7.4)	None	< 4 hours	~8 hours	Rapid aggregation & hydrolysis
With HSA	Human Serum Albumin (0.5%)	~72 hours	> 1 week	Non-covalent binding prevents aggregation
Liposomal (DSPC/Chol)	Phospholipid bilayer	> 1 week	> 1 month	Encapsulation shields from aqueous milieu
With Antioxidants	Ascorbic acid (1 mM)	~24 hours	~48 hours	Reduces oxidative degradation

Protocol 2: Preparing and Characterizing Stable ICG-Albumin Complexes

Aim: To create a stable, monomeric ICG formulation for reproducible NIR-II imaging studies.

Materials:

• ICG (lyophilized)
• Human Serum Albumin (HSA, fatty acid-free)
• Phosphate Buffered Saline (PBS), pH 7.4
• UV-Vis-NIR spectrophotometer
• 0.22 µm syringe filter

Procedure:

• Solution Preparation: Prepare a 1 mg/mL HSA solution in PBS. Pre-warm to 37°C.
• Complex Formation: To 1 mL of the HSA solution, add 10 µL of a 1 mM ICG solution in DMSO (final ICG ~10 µM, HSA ~15 µM). This ensures an HSA:ICG molar ratio >1.5:1, promoting monomeric binding.
• Incubation: Vortex gently and incubate at 37°C for 15 minutes in the dark.
• Characterization: Filter through a 0.22 µm filter. Immediately scan absorption from 600-900 nm. A sharp peak at ~780 nm indicates monomeric ICG. A broadened peak or shoulder at ~700 nm suggests presence of aggregates.
• Storage: Aliquot and store at 4°C in the dark. Use within 48 hours for optimal performance.

Recommendations: For in vivo studies, consider species-matched albumin (e.g., mouse serum albumin for murine models). Always prepare fresh complexes and verify spectral profile prior to injection.

Managing Batch Variability

Commercial ICG exhibits variability in purity, salt content (often sodium iodide), and residual solvents, critically affecting optical properties and nanoparticle loading efficiency.

Protocol 3: Standardized Quality Assessment for a New ICG Batch

Aim: To qualify a new batch of ICG for NIR-II imaging experiments against an in-house standard.

Materials:

• New batch of ICG
• Qualified reference ICG batch (stored desiccated at -20°C)
• Anhydrous DMSO (spectrophotometric grade)
• Analytical balance
• UV-Vis-NIR spectrophotometer

Procedure:

• Preparation of Stock Solutions: Pre-warm vials of ICG to room temperature in a desiccator. Precisely weigh 1.0 mg of both the new and reference ICG. Dissolve each in 1 mL of anhydrous DMSO to make 1 mg/mL master stocks. Vortex thoroughly.
• Absorption Spectral Analysis: Dilute both stocks 1:100 in DMSO. Record absorption spectra from 600-900 nm in a 1 cm path cuvette.
• Key Metrics Calculation:
  • Monomer/Aggregate Ratio: Calculate the ratio of absorbance at 780 nm (monomer peak) to absorbance at 700 nm (aggregate shoulder). Record for both batches.
  • Purity Index: Calculate the ratio A780/A750. A higher ratio (>1.1) indicates higher monomeric purity.
  • Molar Absorptivity: Using the known concentration (from precise weighing), calculate ε at 780 nm using the Beer-Lambert law (A = εcl).
• Performance Test: Using Protocol 1, compare the NIR-II fluorescence intensity and photobleaching half-life of both batches at an identical concentration (e.g., 5 µM in PBS with 0.5% HSA).

Acceptance Criteria: The new batch's monomer/aggregate ratio and molar absorptivity should be within ±10% of the reference batch. NIR-II intensity should be within ±15%.

Diagram 2: ICG Batch Qualification Logic

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for ICG-based NIR-II Studies

Item	Function / Purpose	Key Considerations for Clinical Translation Research
Human Serum Albumin (HSA), Fatty Acid-Free	Stabilizes ICG in aqueous buffers, prevents aggregation, mimics physiological carrier.	Use GMP-grade if moving towards clinical studies. Consider species-specific albumin for preclinical models.
Liposomal Formulation Kits (e.g., DSPC/Cholesterol)	Encapsulates ICG, dramatically improving photostability and circulation half-life.	Size and PEGylation critical for biodistribution. Ensure reproducible, scalable manufacturing.
Anhydrous DMSO (Spectrophotometric Grade)	For preparing precise, aggregate-free primary stock solutions of ICG.	Use low-water content to prevent ICG degradation upon dissolution. Aliquot to minimize water absorption.
Oxygen Scavenging/Deaeration System	Removes dissolved O₂ to study and mitigate oxygen-dependent photobleaching pathways.	Useful for defining the fundamental limits of ICG stability in controlled environments.
NIR-II Calibration Standards	Non-bleaching reference materials (e.g., IR-26 dye in CDCl₃) for system calibration.	Essential for quantitative comparison of ICG signal intensity across experiments and batches.
Size Exclusion Chromatography (SEC) Columns	Separates monomeric ICG from aggregates and checks stability of ICG-complex formulations.	Fast, qualitative check for formulation integrity pre-injection.

Proactive management of ICG's limitations through standardized protocols for photobleaching quantification, albumin-complex stabilization, and rigorous batch qualification is non-negotiable for generating robust, reproducible data in NIR-II imaging research. These practices form a critical foundation for the credible translation of ICG tail emission imaging from the bench towards clinical application.

Proof of Performance: Validating ICG NIR-II Against Standards and Novel Probes

1. Introduction & Context This application note, framed within a thesis on the clinical translation of NIR-II imaging using indocyanine green (ICG) tail emission, details quantitative protocols for benchmarking NIR-II performance against the traditional NIR-I window (700-900 nm). The superior photon scattering and tissue autofluorescence reduction in the NIR-II window (1000-1700 nm) offer transformative potential for deep-tissue, high-resolution in vivo imaging, critical for preclinical research and drug development.

2. Core Quantitative Benchmarks: Comparative Data The following table summarizes key performance metrics from recent literature comparing NIR-II and NIR-I imaging using ICG and other agents.

Table 1: Quantitative Comparison of NIR-II vs. NIR-I Imaging Performance

Performance Metric	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)	Measurement Protocol Summary
Spatial Resolution	~200-300 µm at 3 mm depth	~20-50 µm at 3 mm depth	Measured via full-width-at-half-maximum (FWHM) of a sub-cutaneous capillary or sharp-edged phantom at defined depths in tissue-simulating phantoms or in vivo.
Tissue Penetration Depth	1-3 mm for high contrast	5-10 mm for high contrast	Depth at which the signal-to-background ratio (SBR) drops below a threshold of 2.0, using a point source or vessel in scattering phantoms or animal models.
Signal-to-Background Ratio (SBR)	Moderate (2-5 in deep tissue)	High (5-20+ in deep tissue)	Calculated as (Mean Signal in ROI) / (Mean Signal in Adjacent Background ROI). Measured for labeled tumors or vasculature against surrounding tissue.
Tissue Autofluorescence	High, especially at <800 nm	Negligible above 1000 nm	Quantified by imaging non-injected control subjects under identical laser exposure and acquisition settings.
ICG Tail Emission (≈1300 nm) Contrast	Not applicable	SBR can exceed 10 in vasculature	Administer clinical-grade ICG (low dose, 0.1-0.3 mg/kg) and image after initial vascular clearance (>24h post-injection) to leverage retained probe in target tissues.

3. Detailed Experimental Protocols

Protocol 1: Benchmarking Spatial Resolution & Penetration Depth Objective: Quantify the resolution degradation and signal attenuation as a function of depth for NIR-I vs. NIR-II channels. Materials: NIR-II imaging system with dual NIR-I/NIR-II detection channels; tissue-simulating phantom (e.g., Intralipid or agar with scattering agents); resolution target (1951 USAF or tungsten carbide edge); ICG or IR-12N3 dye. Procedure: 1. Prepare a 1-2% Intralipid phantom (µs' ≈ 1 mm⁻¹) to mimic tissue scattering. 2. Embed a resolution target or a sharp-edged metal foil at the bottom of a container and cover with phantom material at incremental depths (0, 1, 2, 3, 5, 8 mm). 3. Submerge a capillary tube filled with NIR dye (e.g., 100 µM ICG) alongside the target. 4. Acquire co-registered images at NIR-I (800/40 nm filter) and NIR-II (1300/50 nm long-pass filter) using identical laser excitation (e.g., 808 nm). 5. Analysis: * Resolution: Calculate the modulation transfer function (MTF) or measure the edge spread function at each depth. * Penetration: Plot mean signal intensity from the capillary vs. depth. Define penetration limit as depth where SBR < 2.

Protocol 2: In Vivo Vascular Imaging for Contrast (SBR) Measurement Objective: Compare in vivo vascular contrast of ICG in NIR-I vs. NIR-II windows. Materials: Anesthetized mouse model; clinical-grade ICG; tail vein catheter; NIR-II imaging system. Procedure: 1. Acquire a pre-injection background image for both spectral channels. 2. Inject ICG via tail vein (bolus, 0.1 mg/kg in 100 µL saline). 3. Record dynamic video for 5 mins (peak vascular phase) and static images at 24h (tail emission phase). 4. Analysis: * Draw regions of interest (ROIs) over major vessels (e.g., femoral artery) and adjacent muscle tissue. * Calculate SBR = (Mean Vessel Signal - Mean Background Signal) / Mean Background Signal for each time point and channel. * Compare peak SBR (1-2 min p.i.) and late-phase SBR (24h p.i.).

4. Visualizing the Workflow and Advantage

Title: ICG Pharmacokinetics & Optimal Imaging Windows

5. The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Benchmarking Studies

Item	Function & Rationale
Clinical-Grade Indocyanine Green (ICG)	FDA-approved dye; enables study of 'tail emission' in NIR-II for direct clinical translation path. Low-cost and readily available.
NIR-IIb Filter (e.g., 1500 nm LP)	Isolates emission >1500 nm (NIR-IIb), where tissue scattering is minimal, for ultimate penetration depth benchmarks.
Tissue-Simulating Phantom Kit (Intralipid, India Ink, Agar)	Provides standardized, reproducible medium for controlled resolution and penetration depth measurements without animal variability.
Calibrated Resolution Target (USAF 1951, SiR-NIR)	Enables precise, quantitative measurement of spatial resolution (in LP/mm) for system and protocol validation.
High-Sensitivity InGaAs Camera (Cooled, TE)	Essential detector for NIR-II light, which is of low abundance. Cooling reduces dark noise for high-fidelity imaging.
Dedicated NIR-II Imaging Software (e.g., LabVIEW, Home-built)	Allows for synchronized control of laser, filter wheels, and camera, plus spectral unmixing and time-traced analysis.

The clinical translation of NIR-II (1000-1700 nm) imaging promises revolutionary advances in surgical guidance and disease diagnosis. A central thesis in this field posits that leveraging the "tail emission" of the clinically approved dye Indocyanine Green (ICG) (beyond 1000 nm) represents the most rapid pathway to clinical adoption, bypassing lengthy regulatory hurdles. This application note provides a direct, quantitative comparison between ICG tail emission and novel, purpose-built synthetic NIR-II fluorophores, equipping researchers with the data and protocols needed to evaluate each approach for their specific translational research.

Table 1: Photophysical & Performance Comparison

Property	ICG (Tail Emission)	Novel NIR-II Fluorophores (e.g., CH1055, IR-FGP)
Peak Emission (nm)	~820 nm (primary), tail >1000 nm	1000 - 1060 nm (typical for organic)
Brightness (ε × Φ) in NIR-II	Very Low (~0.1-1 M⁻¹cm⁻¹)*	Moderate to High (10⁴ - 10⁵ M⁻¹cm⁻¹)
Quantum Yield (NIR-II)	<0.1%	0.5% - 10% (in serum/particles)
Tissue Penetration Depth	Moderate (enhanced over NIR-I)	Superior (reduced scattering at longer λ)
Clinical Approval Status	FDA-approved for diagnostic use	Preclinical stage; regulatory path required
Excitation Source	Standard 785-808 nm laser/diode	785-980 nm laser, depending on fluorophore
Administration Route	Intravenous (off-label for imaging)	Intravenous (investigational)
Optimal Imaging Window	Immediate (vascular) to 24h (targeted)	1-24h post-injection (targeted agents)
Key Limitation	Extremely weak signal, high background	Toxicity/biodistribution data pending

*Estimated from published attenuation of emission tail.

Table 2: In Vivo Performance Metrics (Representative Data)

Metric	ICG Tail Emission Imaging	Novel NIR-II Fluorophore Imaging
Signal-to-Background Ratio (Tumor)	1.5 - 3.0	5.0 - 15.0
Vessel Imaging Resolution	~100-200 µm	~20-50 µm (sub-capillary)
Real-time Frame Rate (fps)	10 - 25 (limited by signal)	25 - 100+
Dose (mg/kg)	0.1 - 5.0 (standard clinical)	0.01 - 0.5 (for small molecules)

Application Notes

For ICG Tail Emission: The primary advantage is immediate deployability in human studies. Protocols must be optimized for maximal signal extraction: use sensitive InGaAs cameras, acquire long exposure times (>100 ms), and employ robust background subtraction algorithms. Imaging is most effective for macro-vascular and hepatobiliary imaging.

For Novel NIR-II Fluorophores: These agents offer a step-change in performance. Researchers can achieve microscopic resolution in vivo. Key considerations include particle formulation (for biocompatibility and brightness enhancement), determining pharmacokinetics, and conducting comprehensive toxicology studies. The trade-off is a multi-year development and regulatory timeline.

Detailed Experimental Protocols

Protocol 4.1: NIR-II Imaging System Calibration & Setup

Objective: Establish a standardized imaging platform for comparative studies.

• Instrumentation: Use a 808 nm laser (for ICG) or 980 nm laser (for many NIR-II fluorophores) for excitation. Employ a cooled, two-dimensional InGaAs camera (900-1700 nm detection) with a 1000 nm long-pass emission filter.
• Calibration:
  • Spatial: Use a USAF 1951 resolution target. Image with 5 ms exposure. Calculate modulation transfer function.
  • Intensity: Prepare serial dilutions of IR-26 dye (QY=0.05% in DCE) as a reference standard. Acquire images at fixed laser power and exposure time. Plot integrated intensity vs. concentration to generate a system response curve.
• Background Subtraction: Acquire an image of the anesthetized animal prior to contrast agent injection under identical settings. Use this as a background frame for digital subtraction post-injection.

Protocol 4.2: In Vivo Comparative Biodistribution & Pharmacokinetics

Objective: Quantify the in vivo behavior and performance limits of ICG vs. a novel NIR-II fluorophore.

• Animal Model: Use nude mice bearing a subcutaneous xenograft tumor (e.g., U87MG).
• Agent Administration:
  • ICG: Prepare a 0.1 mg/mL solution in sterile water. Inject via tail vein at 2.5 mg/kg.
  • NIR-II Fluorophore (e.g., CH1055-PEG): Prepare a 0.1 mM solution in PBS. Inject via tail vein at 0.1 µmol/kg (approx. 0.05 mg/kg).
• Imaging Timeline: Anesthetize mouse and place on heated stage. Acquire baseline image. Inject agent and acquire images at t = 30s, 1, 2, 5, 10, 30, 60, 120, and 240 minutes post-injection. Maintain consistent geometry and settings.
• Data Analysis: Define regions of interest (ROIs) over the tumor, muscle (background), liver, and a major vessel. Calculate Signal-to-Background Ratio (SBR) as (Mean IntensityTumor) / (Mean IntensityMuscle). Plot SBR vs. time for both agents. Calculate tumor-to-liver ratios at the peak time point.

Protocol 4.3: Resolution Limit Assessment via Cerebral Vasculature Imaging

Objective: Demonstrate the superior resolution capability of bright NIR-II agents.

• Cranial Window Preparation: Perform a thinned-skull or open cranial window surgery on a C57BL/6 mouse under anesthesia and stereotaxic guidance.
• Imaging: After recovery, inject either ICG (5 mg/kg) or a novel NIR-II fluorophore (0.2 µmol/kg). Using the calibrated NIR-II system, acquire high-resolution images (50 ms exposure) of the cortical vasculature.
• Analysis: Use the ImageJ plugin "AngioTool" to quantify vascular parameters: vessel density, junction density, and average vessel diameter. Compare the minimum resolvable vessel diameter between the two imaging cohorts.

Diagrams

Clinical Translation Decision Pathway

In Vivo NIR-II Imaging Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Imaging Research

Item	Function/Benefit	Example/Notes
ICG, Diagnostic Grade	Clinically approved dye for tail emission studies.	PULSION (Germany), Ensure sterility for in vivo use.
Prototype NIR-II Fluorophore	High-performance alternative to ICG.	CH1055, IR-FGP, or similar from vendors like Lumiprobe.
InGaAs Camera (2D)	Essential detector for >1000 nm light.	Models from NIT, Princeton Instruments, or Teledyne FLIR.
808 nm & 980 nm Lasers	Excitation sources for ICG and NIR-II dyes.	Continuous wave diode lasers with fiber output.
Long-pass Emission Filters	Blocks excitation laser & NIR-I light.	Semrock LP1000-1300 nm filters.
IR-26 Reference Dye	NIR-II quantum yield standard (QY=0.05%).	Sigma-Aldrich; dissolve in 1,2-dichloroethane.
Image Analysis Software	For quantification of SBR, resolution, etc.	ImageJ (FIJI) with custom macros, or commercial options.
Sterile PBS/Saline	Vehicle for dye formulation and dilution.	Essential for in vivo injections.

Application Notes

The clinical translation of NIR-II (1000-1700 nm) fluorescence imaging with Indocyanine Green (ICG), leveraging its tail emission beyond 1000 nm, necessitates robust validation against established clinical standards. These Application Notes detail the framework for designing validation studies that quantitatively correlate NIR-II/ICG imaging data with histopathological analysis and standard-of-care imaging modalities (e.g., MRI, CT, US). Successful validation establishes NIR-II imaging as a reliable biomarker for surgical guidance, therapeutic monitoring, and diagnostic assessment.

Key Validation Objectives:

• Sensitivity & Specificity: Determine the ability of NIR-II signal to accurately identify diseased tissue (e.g., tumor margins, atherosclerotic plaques) confirmed by histology.
• Quantitative Correlation: Establish statistical relationships between in vivo NIR-II metrics (e.g., Signal-to-Background Ratio, SBR; fluorescence intensity) and ex vivo histopathological features (e.g., cellular density, receptor expression) or standard imaging parameters (e.g., SUVmax from PET, enhancement on MRI).
• Superiority or Non-Inferiority: Demonstrate advantages over traditional NIR-I (700-900 nm) imaging or equivalence to current imaging standards for specific clinical endpoints.

Experimental Protocols

Protocol 1: Intraoperative Tumor Margin Assessment & Correlation with Histopathology

Objective: To validate the accuracy of NIR-II/ICG imaging in delineating primary tumor margins during surgery against post-resection histopathological analysis.

Materials: See Research Reagent Solutions table. Pre-operative: Administer ICG (dose: 2.5 mg/kg, IV) 24 hours prior to surgery for optimal tumor accumulation and background clearance. Intraoperative Imaging:

• Expose the surgical field. Acquire white-light and NIR-I (800 nm) reference images.
• Switch to NIR-II imaging system (laser excitation: 808 nm; emission filter: >1000 nm or 1000-1300 nm bandpass).
• Acquire fluorescence images of the in situ tumor and surrounding tissue. Use consistent camera settings (gain, integration time).
• Mark the perceived tumor boundary based on NIR-II signal thresholding (SBR > 2.0) on the tissue surface using sterile sutures.
• Perform resection according to standard surgical practice plus NIR-II guidance. Ex Vivo Correlation:
• Image the resected specimen immediately under NIR-II to confirm margin fluorescence.
• Ink the surgical margins according to anatomical orientation.
• Section the specimen perpendicularly along the plane corresponding to the NIR-II-imaged surface. Slice into 5-mm sections.
• For each section, map areas of high NIR-II signal onto a corresponding tissue diagram.
• Submit all sections for standard H&E staining and optional immunohistochemistry (IHC) for relevant biomarkers (e.g., Cytokeratin for carcinomas).
• A blinded pathologist will assess the presence of tumor cells at the inked margins and within the mapped fluorescent regions.

Data Analysis: Co-register histological maps with NIR-II fluorescence maps. Calculate sensitivity (true positive rate) and specificity (true negative rate) of NIR-II signal for predicting tumor-positive margins on histology.

Protocol 2: Quantitative Correlation of NIR-II Angiography with Contrast-Enhanced MRI

Objective: To validate NIR-II/ICG angiography metrics against dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters for assessing tissue perfusion.

Materials: See Research Reagent Solutions table. Subject Preparation: Animal model or human subject enrolled for a clinical study requiring both MRI and intraoperative imaging. DCE-MRI Protocol:

• Perform baseline T1-weighted MRI.
• Administer Gadolinium-based contrast agent (standard clinical dose) as a bolus.
• Acquire dynamic series over the region of interest (ROI) for at least 5 minutes.
• Generate parametric maps (e.g., K^trans [volume transfer constant], AUC [area under the curve]). NIR-II/ICG Angiography Protocol (within 48 hours of MRI):
• Expose the same anatomical region surgically.
• Set up NIR-II imaging system for rapid acquisition (>10 fps).
• Administer a bolus of ICG (0.1 mg/kg, IV).
• Record dynamic fluorescence video for 3-5 minutes.
• Generate time-intensity curves for identical ROIs defined on MRI. Data Correlation:
• Co-register anatomical landmarks from MRI and NIR-II images.
• Extract quantitative parameters from NIR-II dynamics: Time-to-Peak (TTP), Maximum Intensity (I_max
• Perform linear regression analysis between NIR-II parameters (e.g., I_max) and DCE-MRI parameters (e.g., AUC) across multiple ROIs/subjects.

Data Presentation

Table 1: Summary of NIR-II/ICG Validation Metrics Against Histopathology (Hypothetical Data from a Breast Cancer Study)

Metric	NIR-II/ICG Imaging Result	Histopathology Gold Standard	Calculation	Outcome Value
True Positive (TP)	Fluorescent Margin	Tumor cells present	-	18 margins
True Negative (TN)	Non-fluorescent Margin	No tumor cells	-	65 margins
False Positive (FP)	Fluorescent Margin	No tumor cells (e.g., inflammation)	-	7 margins
False Negative (FN)	Non-fluorescent Margin	Tumor cells present	-	2 margins
Sensitivity	-	-	TP / (TP + FN)	90.0%
Specificity	-	-	TN / (TN + FP)	90.3%
Positive Predictive Value (PPV)	-	-	TP / (TP + FP)	72.0%
Negative Predictive Value (NPV)	-	-	TN / (TN + FN)	97.0%

Table 2: Correlation Coefficients Between NIR-II Angiography and DCE-MRI Perfusion Parameters

NIR-II Dynamic Parameter	DCE-MRI Parameter	Pearson Correlation Coefficient (r)	p-value	Number of ROIs (n)
Maximum Intensity (Imax)	AUC (0-60s)	0.87	<0.001	45
Wash-in Slope	Ktrans	0.79	<0.001	45
Time-to-Peak (TTP)	TTP (from MRI)	0.91	<0.001	45

Visualizations

Diagram 1: Clinical Validation Workflow for NIR-II Imaging

Diagram 2: Key Signaling & Accumulation Pathways for ICG in Tumors

The Scientist's Toolkit: Research Reagent Solutions

Item	Function/Justification
ICG for Injection (FDA-approved)	The sole NIR-II fluorophore with established human safety profiles, used for its "tail emission" in the NIR-II window.
NIR-II Imaging System	Contains a 808 nm laser for excitation, InGaAs or other NIR-II-sensitive cameras, and filters (e.g., longpass >1000 nm) to block excitation light and NIR-I emission.
Standard Imaging Contrast Agents	Gadolinium (MRI), Iohexol (CT), [18F]FDG (PET). Essential for generating correlative data from established clinical modalities.
IHC Antibody Panel	Antibodies against disease-specific biomarkers (e.g., CD31 for vasculature, PSMA for prostate cancer) to correlate fluorescence with molecular pathology.
Tissue Sectioning & Mapping Apparatus	A precision tissue slicer and custom grid molds to ensure accurate spatial correspondence between imaging surfaces and histology slides.
Co-registration Software	Advanced image analysis software (e.g., 3D Slicer, MATLAB toolboxes) capable of multi-modal rigid/non-rigid image registration.

Indocyanine green (ICG), a near-infrared (NIR) fluorescent dye approved by the FDA in 1959, has recently gained significant attention for its utility in the "second near-infrared window" (NIR-II, 1000-1700 nm) via its tail emission. This application is central to a broader thesis on accelerating clinical translation of optical imaging. ICG's established safety profile, low cost, and well-understood pharmacokinetics present a compelling cost-benefit and regulatory advantage over novel, non-approved NIR-II fluorophores. This document outlines detailed application notes and protocols for leveraging ICG's NIR-II emission in preclinical research aimed at rapid clinical translation.

Table 1: Comparative Cost-Benefit Analysis

Parameter	ICG	Novel Synthetic NIR-II Fluorophores (e.g., Quantum Dots, SWCNTs, Organic Dyes)
FDA Approval Status	Approved for human use (since 1959)	Investigational New Drug (IND) required; not approved
Estimated Cost per Dose (Preclinical)	$5 - $50	$500 - $5000+
Time to First-in-Human Study	Months (protocol amendment)	3-5+ years (full IND/CTA pathway)
Known Toxicity Profile	Extensive, well-documented	Limited, requires full characterization
Manufacturing & Quality Control	Established GMP suppliers; simple chemistry	Complex synthesis; novel QC protocols needed
Excretion Pathway	Hepatobiliary (well-known)	Often unclear; requires detailed toxicokinetics

Table 2: Optical Properties in the Context of Clinical Translation

Property	ICG (in serum, ~800 nm peak)	ICG (NIR-II tail emission >1000 nm)	Idealized Novel NIR-II Dye
Excitation (nm)	~780	~808	~808 or ~980
Emission Peak (nm)	~820	Broad tail to 1300+	1000-1400
Tissue Penetration Depth	Moderate (~5-10 mm)	Improved (~10-20 mm)	High (>20 mm)
Background (Tissue Autofluorescence)	Low	Very Low	Extremely Low
Clinical Imaging System Availability	Widespread (laparoscopic, open)	Emerging; requires modified/advanced detectors	Specialized research-only

Application Notes & Protocols

Protocol 1: In Vivo NIR-II Imaging Using ICG Tail Emission for Vascular Mapping

Objective: To perform real-time, high-resolution vascular imaging in a rodent model using clinically relevant ICG doses. Rationale: Demonstrates feasibility of NIR-II imaging with an already-approved agent.

Materials (Research Reagent Solutions Toolkit):

• ICG (PULSION or equivalent): Clinical-grade fluorophore. Reconstitute per manufacturer instructions.
• NIR-II Imaging System: InGaAs camera or superconducting nanowire single-photon detector (SNSPD) system with 808 nm laser excitation and 1000 nm long-pass emission filter.
• Animal Model: Athymic nude mouse or other appropriate model.
• Sterile Saline (0.9%): For dilution and injection.
• Isoflurane/Oxygen Mix: For anesthetic maintenance.
• Heating Pad: For physiological maintenance during imaging.
• Image Analysis Software (e.g., Fiji, Living Image): For quantification.

Detailed Methodology:

• System Calibration: Power on the NIR-II imaging system and allow it to stabilize for 30 minutes. Set laser excitation to 808 nm at a power density not exceeding 20 mW/cm² (safe for skin). Ensure the 1000 nm long-pass emission filter is correctly positioned.
• Animal Preparation: Anesthetize the mouse using 3% isoflurane and maintain at 1.5-2% in oxygen. Place the animal prone on the heated stage. Depilate the imaging area (e.g., hindlimb or dorsal skin) to reduce light scattering.
• Baseline Image Acquisition: Acquire a pre-contrast NIR-II image (exposure: 50-200 ms) to assess background.
• ICG Administration: Prepare a sterile solution of ICG in saline at 0.1 mg/mL. Inject 100 µL (0.01 mg, ~0.5 mg/kg) intravenously via the tail vein as a bolus.
• Dynamic Image Acquisition: Initiate continuous image acquisition (1-5 frames per second) immediately post-injection for 2-3 minutes to capture the first-pass vascular dynamics.
• Static Imaging: Acquire high-signal-to-noise ratio images at 5-10 minutes post-injection for detailed vascular mapping.
• Data Analysis: Use software to generate time-intensity curves from regions of interest (ROI) over major vessels. Calculate metrics such as perfusion rate and signal-to-background ratio (SBR) in the NIR-II window.

Protocol 2: Image-Guided Surgery Simulation Using ICG NIR-II Emission

Objective: To simulate tumor resection guided by ICG's NIR-II signal, highlighting margin assessment. Rationale: Directly translates to ongoing clinical trials using ICG in oncology surgery.

Materials (Additions to Toolkit):

• Tumor-Bearing Mouse Model: Subcutaneous xenograft (e.g., U87MG glioblastoma).
• Microsurgical Tools: Forceps, scissors.
• White Light and NIR-II Co-registration System: Or sequential imaging capability.

Detailed Methodology:

• Tumor Model Development: Allow subcutaneous tumor to grow to ~5-8 mm in diameter.
• ICG Administration: 24 hours prior to imaging/surgery, inject ICG intravenously at 2 mg/kg (passive targeting via EPR effect).
• Pre-Resection Imaging: Anesthetize the animal. Acquire co-registered white light and NIR-II images of the tumor region. Define the tumor boundary based on the NIR-II signal.
• Simulated Resection: Under white light guidance, make a superficial incision. Use the real-time NIR-II imaging feed to identify the primary tumor mass and resect it.
• Margin Assessment: After presumed gross total resection, image the surgical bed in the NIR-II window. Any residual fluorescent signal indicates possible positive margins.
• Ex Vivo Validation: Excise the residual fluorescent tissue and the main tumor mass. Image ex vivo and process for histology (H&E) to correlate NIR-II signal with cellular pathology.

Visualizations

Title: ICG NIR-II Imaging Workflow

Title: Regulatory Pathway Decision Tree

The Scientist's Toolkit: Essential Research Reagent Solutions

Item	Function & Relevance
Clinical-Grade ICG (Lyophilized)	The core FDA-approved fluorophore. Must be reconstituted fresh for each experiment to avoid aggregation, which quenches fluorescence.
808 nm Diode Laser	Optimal excitation source for ICG. Power must be calibrated for animal safety (<20 mW/cm² on skin surface).
InGaAs Camera with 1000 nm LP Filter	Essential detector for capturing ICG's weak but valuable NIR-II tail emission (>1000 nm). Cooling reduces dark noise.
Sterile Saline (0.9% NaCl)	Universal diluent for ICG and vehicle control for injections. Ensures biocompatibility.
Tail Vein Injection Setup (27-30G needles, warming chamber)	Enables reliable intravenous bolus delivery for dynamic contrast-enhanced studies.
Hair Removal Cream	Critical for reducing light scattering and absorption by fur, maximizing signal from tissue.
Anatomical & Fluorescent Phantoms	Used for daily system calibration, validation of resolution, and co-registration accuracy.
ISO-compliant Anesthesia System	Ensures animal welfare and physiological stability, which is crucial for reproducible pharmacokinetic data.

Application Note: NIR-II Imaging of Tumor Vasculature & Drug Delivery in Oncology

Background: The enhanced permeability and retention (EPR) effect in tumors is a cornerstone of nanomedicine. Real-time, deep-tissue visualization of drug carrier accumulation remains a challenge for clinical translation. NIR-II imaging using the tail emission of Indocyanine Green (ICG, >1300 nm) offers superior resolution and penetration.

Quantitative Data: Table 1: Comparison of Imaging Modalities for Tumor Vasculature

Imaging Parameter	NIR-I (800-900 nm)	NIR-II (ICG Tail, 1500-1700 nm)	Clinical MRI (T1-weighted)
Spatial Resolution	~3-5 mm	~20-50 μm	~1-2 mm
Temporal Resolution	Seconds	Seconds to Minutes	Minutes
Penetration Depth	1-3 mm	5-10 mm	Unlimited
Signal-to-Background	Low-Moderate	High (Up to 5-fold improvement)	High
Quantification of EPR	Semi-quantitative	Quantitative	Semi-quitative

Experimental Protocol: NIR-II Imaging of Liposomal Doxorubicin (ICG-Lipo-DOX) Delivery

• Animal & Tumor Model: Inoculate 1x10^6 MDA-MB-231 cells (human breast cancer) subcutaneously into the right flank of female nude mice (n=5). Proceed with imaging when tumor volume reaches 300-500 mm³.
• Probe Preparation: Synthesize ICG-loaded, DOX-conjugated PEGylated liposomes (ICG-Lipo-DOX) via thin-film hydration and extrusion (100 nm filter). Purify via size-exclusion chromatography. Final formulation: 1 mg/mL DOX, 0.1 mg/mL ICG in PBS.
• Imaging Protocol: a. Anesthetize mouse with 2% isoflurane. b. Acquire a pre-injection baseline image using a NIR-II imaging system (e.g., InGaAs camera, 1500 nm long-pass filter, 808 nm excitation laser at 100 mW/cm²). c. Administer 100 μL of ICG-Lipo-DOX via tail vein injection. d. Acquire serial NIR-II images at 1, 5, 15, 30, 60, 120, and 240 minutes post-injection. Keep laser power and camera settings constant. e. Euthanize mouse at 4h or 24h, excise tumor and major organs for ex vivo imaging.
• Data Analysis: Draw regions of interest (ROIs) over tumor, liver, and muscle. Plot fluorescence intensity (counts/sec) over time. Calculate tumor-to-background ratio (TBR) and area under the curve (AUC).

Title: NIR-II Drug Delivery Study Workflow

---

Application Note: Cerebrovascular Imaging & Ischemic Stroke Assessment in Neurology

Background: Dynamic imaging of cerebral blood flow (CBF) and blood-brain barrier (BBB) integrity is critical for stroke evaluation. NIR-II imaging through the intact skull provides a non-invasive method for assessing penumbra and therapeutic intervention efficacy.

Quantitative Data: Table 2: NIR-II vs. Traditional Methods in Stroke Models

Assessment Metric	Laser Doppler Flowmetry	NIR-II Angiography	Post-mortem Histology
Field of View	Single point	Wide-field (Whole hemisphere)	Whole brain (sectioned)
Dynamic CBF Measurement	Yes	Yes	No
BBB Leakage Quantification	No	Yes (with contrast agent)	Yes (IgG staining)
Temporal Resolution	Millisecond	1-10 frames/sec	Endpoint only
Invasiveness	Craniotomy required	Non-invasive through skull	Terminal

Experimental Protocol: Middle Cerebral Artery Occlusion (MCAO) & Reperfusion Imaging

• Stroke Model: Induce transient focal ischemia in C57BL/6 mice (n=7) using the intraluminal filament method (7-0 silicone-coated filament) to occlude the right MCA for 60 minutes. Confirm successful occlusion by Laser Doppler flowmetry drop >70%.
• NIR-II Angiography: At designated time points (e.g., 1h post-reperfusion, 24h), anesthetize the mouse and secure in a stereotaxic frame. Shave the head. Intravenously inject ICG (0.1 mg/kg in 100 μL saline).
• Imaging Setup: Position the NIR-II camera (InGaAs, 1300 nm LP filter) perpendicular to the skull. Use an 808 nm laser for excitation. Acquire a rapid sequence of images (10 fps) immediately after injection to capture the first-pass bolus for angiography.
• BBB Permeability Imaging: 30 minutes after ICG injection, acquire a steady-state image. Persistent signal indicates ICG extravasation due to BBB disruption.
• Data Analysis: For angiography, calculate relative CBF by analyzing the time-to-peak (TTP) in the ischemic vs. contralateral hemisphere. For BBB leakage, quantify fluorescence intensity in the ischemic region and normalize to the contralateral side.

Title: Stroke Imaging & BBB Assessment Pathway

---

Application Note: Coronary Angiography & Atherosclerotic Plaque Imaging in Cardiovascular Research

Background: High-resolution coronary angiography and identification of vulnerable, inflamed atherosclerotic plaques are essential for preventing acute coronary events. NIR-II imaging offers a low-cost, high-throughput alternative to intravascular ultrasound (IVUS) or OCT in preclinical models.

Quantitative Data: Table 3: Intravascular Imaging Modalities for Atherosclerosis

Modality	NIR-II Fluorescence	IVUS	OCT
Resolution	50-100 μm	100-200 μm	10-20 μm
Penetration	2-5 mm	4-8 mm	1-2 mm
Plaque Inflammation	Yes (with targeted probes)	No	No
Lipid Core Detection	Yes (with contrast)	Indirect (echolucency)	Yes
Real-time 3D	Yes	Yes	Yes

Experimental Protocol: In Vivo Coronary Angiography & Plaque Targeting

• Animal Model: Use ApoE-/- mice fed a high-fat diet for 16 weeks to develop advanced atherosclerotic plaques in the aortic root and brachiocephalic artery.
• Surgical Preparation: Anesthetize and intubate the mouse. Perform a left thoracotomy to expose the heart. Maintain physiological temperature.
• NIR-II Coronary Angiography: Inject a bolus of ICG (0.05 mg/kg) via the jugular vein. Simultaneously, acquire high-speed NIR-II video (30 fps) of the exposed heart using a macro lens. Use ECG gating if available to image during diastolic periods of minimal motion.
• Targeted Plaque Imaging: Allow 24h for ICG clearance. Inject a targeted NIR-II probe (e.g., anti-VCAM-1 antibody conjugated to a NIR-II dye) intravenously. After 48h for optimal target-to-background, re-image the aortic arch ex vivo.
• Analysis: For angiography, measure coronary artery diameter. For plaque imaging, co-localize NIR-II signal with Oil Red O staining on cryosections. Calculate target-to-background ratio (TBR) for specific vs. isotype control probe.

Title: Cardiovascular Imaging Logic Flow

---

The Scientist's Toolkit: Key Research Reagent Solutions

Table 4: Essential Materials for NIR-II Imaging with ICG Tail Emission

Item	Function & Application
ICG (Indocyanine Green)	FDA-approved dye; NIR-II emitter (>1300 nm). Used as a free dye for angiography and perfusion imaging, or as a payload/component in nanocarriers.
PEGylated Liposomes	Versatile nanocarrier platform. Encapsulates ICG and drugs (e.g., DOX) for EPR-based tumor targeting and pharmacokinetic studies via NIR-II imaging.
Targeting Ligands (e.g., anti-VCAM-1, RGD peptides)	Conjugated to NIR-II probes for molecular imaging of specific biomarkers (inflammation, angiogenesis) in plaques or tumors.
NIR-II Imaging System	Includes: 808 nm laser for excitation, InGaAs camera (sensitive 900-1700 nm), long-pass filters (>1300 nm, 1500 nm). Essential for detecting ICG tail emission.
Isoflurane Anesthesia System	Provides stable, long-duration anesthesia for in vivo time-series imaging, ensuring minimal animal motion artifact.
Matrigel	Basement membrane matrix for consistent subcutaneous tumor cell inoculation in oncology models.
Silicone-Coated Filaments (7-0)	For inducing transient Middle Cerebral Artery Occlusion (MCAO) in rodent stroke models.
High-Fat Diet (e.g., 40% kcal from fat)	Induces hyperlipidemia and accelerates the development of atherosclerotic plaques in ApoE-/- mouse models for cardiovascular research.

Conclusion

ICG tail emission NIR-II imaging represents a powerful, immediately translatable paradigm shift in biomedical optics, leveraging a clinically approved agent to unlock superior imaging depth and clarity. The foundational science confirms a robust, though weak, NIR-II signal; methodological refinements enable practical surgical and diagnostic applications; and systematic troubleshooting can yield significantly enhanced performance. Crucially, validation confirms that while novel fluorophores may offer brighter signals, ICG provides an unmatched combination of safety, regulatory pathway, and cost-effectiveness for near-term clinical impact. Future directions should focus on standardized imaging protocols, AI-enhanced signal processing, and combination therapies, solidifying ICG's role as a cornerstone for the widespread clinical adoption of NIR-II imaging in precision medicine and interventional guidance.